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From Discovery to Treatment; Three decades of HIV and AIDS 
It has been more than 30 years since Human Immunodeficiency Virus (HIV) was 
discovered as the causative agent of Acquired Immunodeficiency Syndrome 
(AIDS) (1, 2). Since the first identification, HIV has caused more than 25 million 
deaths and infected at least 60 million people. Despite the development of 
antiretrovirals and increased understanding of viral biology, HIV continues to be a 
major global public health problem. According to the United Nations AIDS report 
on the global AIDS epidemic, there are still more than 30 million people living 
with HIV (3).  
 
HIV primarily infects and destroys CD4 positive T cells and macrophages (1). 
According to Centers for Disease Control (CDC) criteria, HIV infection reaches 
the stage of AIDS when CD4 T cell count drops below 200 cells/µL (Normal level 
ranges from 500 to 1000 cells/µL) (4). In untreated cases this is usually 
accompanied by opportunistic infections such as toxoplasmosis and Kaposi's 
Sarcoma (5).  
 
AIDS was first reported in 1981 at the CDC publication morbidity and mortality 
weekly report. The report included a case history of five homosexual men from 
Los Angeles who were diagnosed with a rare lung infection called Pneumocystis 
carinii pneumonia which was thought to be caused by a cellular immune 
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dysfunction (6). This report prompted other case reports around the country and 
the world. Two years later two separate groups isolated a retrovirus related to 
Human T cell Leukemia Virus (HTLV) from AIDS patients. Even though these 
groups initially called this virus HTLV-III and LAV (Lymphadenopathy Associated 
Virus), it was later renamed HIV based on sequencing and phylogeny analysis 
(1, 2). The original virus that caused the epidemic was later re-classified as HIV-1 
after the discovery of a different subtype of HIV (called HIV-2) that is closely 
related to simian immunodeficiency virus (SIV) found in sooty mangabeys (7). 
Evolutionary analysis revealed that HIV-1 most likely evolved from chimpanzees 
infected with SIV and jumped to humans sometime in early 20th century (8). 
 
Despite the optimism for vaccine development soon after the discovery of the 
virus, to date vaccine trials have not been successful and today no vaccine is 
available for preventing HIV infection. In contrast, development of several small 
molecular drugs called antiretrovirals over the years has made HIV a chronic, 
manageable condition in parts of the world where access to these drugs is fairly 
easy. The first FDA approved anti HIV drug came in the form of a nucleoside 
analog reverse transcriptase inhibitor called azidothymidine (AZT) in 1987 (9). 
While development of AZT was a significant achievement in the fight against 
AIDS, high mutation rate of the error prone viral reverse transcriptase led to rapid 
emergence of drug resistant viruses (10). Following testing and approval of 
multiple different drugs in the mid 90s targeting different activities of the virus, the 
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most important breakthrough in treatment of HIV and AIDS came in the form of 
Highly Active Antiretroviral Therapy (HAART). Using combination of three or 
more antiretrovirals HAART aims to reduce the emergence of drug resistant viral 
mutants (11, 12). Today with an arsenal of more than 20 antiretrovirals HAART is 
the standard treatment for managing HIV infection (Table 1-1). 
Antiretrovirals against HIV have been mostly successful in turning the infection 
into a chronic condition when the treatment is available. However even with 
multiple different classes of FDA approved antiretrovirals that target different 
parts of the viral replication cycle (Table 1-1), evolution of drug resistance is 
inevitable especially for a rapidly mutating virus like HIV (1, 13-15). Even with an 
effective treatment like HAART, keeping viral replication under control requires 
strict patient adherence that comes with great personal and financial cost. In 
addition, majority of antiretrovirals only target two HIV proteins; reverse 
transcriptase and protease. Therefore if cross resistance to the same type of 
drugs occurs in a patient, treatment options can become very limited (15). All 
these reasons make identification of new therapeutic targets a high priority in HIV 
research. An attractive way to target HIV-1 life cycle that may be less sensitive to 
viral mutagenesis is the direct targeting of host cell factors that are utilized by the 
virus. For this reason in recent years a substantial effort has been put to 
identification of "druggable" host cell factors that are involved in HIV-1 replication. 
First one of these came in the form of an allosteric modulator of one of the co-
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receptors of HIV, CCR5, called maraviroc (16). This drug was FDA approved in 
2007 and became the first antiretroviral that targets a host protein. 
 
Genome of HIV-1 
HIV-1 belongs to the lentivirus (lenti meaning slow, named due to the slow 
development of the disease) genus of the family retroviridae (17). Members of 
this family of viruses contain a single stranded positive sense RNA genome that 
is reverse transcribed by a virally encoded polymerase called reverse 
transcriptase to double stranded DNA which is subsequently integrated into the 
host genome. A representative structure of the viral particle is shown in Figure 1-
1. Viral double stranded DNA genome is characterized by long terminal repeat 
(LTR) regions at each end composed of sequence blocks called U3, R and U5 
(Figure 1-2). All retroviruses encode three main genes; gag, pol and env that 
encode polyproteins which are cleaved into subunits by proteases (Figure 1-2). 
The gag gene encodes for the structural subunits of the virus, matrix (MA), 
capsid (CA) and nucleocapsid (NC). The pol gene encodes for the enzymes of 
the virus, protease (PR), reverse transcriptase (RT) and integrase (IN). The env 
gene encodes for the surface proteins, called gp120 and gp41 that are used for 
binding and entry into the target cell. For most retroviruses (including HIV-1) due 
to a translational stop codon at the end of the gag gene, expression of pol gene 
requires a ribosomal frameshift which leads to the production of GagPol 
polyprotein (18). Without this frameshift only Gag polyprotein is expressed. In 
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addition to these core genes, some retroviruses including HIV-1 also encode 
accessory proteins which are involved in regulation of viral replication and 
evasion of the immune system. For HIV-1 these proteins are; vpu (viral protein u) 
which has roles in downregulating restriction factor Tetherin (19, 20), tat 
(transactivator of transcription) which is required for viral transcription (21), rev 
(regulator of viral protein expression) which exports viral mRNA to cytoplasm 
(22), vif (viral infectivity factor) which counteracts cellular restriction factor 
APOBEC3G (23), vpr (viral protein r) which has roles in nuclear import of viral 
cDNA and arrests cells division (24) and nef (negative regulatory factor) which 
downregulates cell surface expression of the receptor CD4 and MHC-I to avoid 
detection by the immune system (25).  
 
HIV-1 Life Cycle 
For the purposes of this dissertation HIV-1 replication cycle is divided into two 
phases: The early phase begins with binding and entry of the virus to the host 
cell and ends with integration of the viral genome to the host chromosome. The 
late phase starts with expression of viral proteins from the proviral genome and 
ends with the maturation of viral proteins after the budding of the viral particle. A 
diagram of the replication cycle of HIV-1 is shown in Figure 1-3. 
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Early phase 
As an enveloped virus, HIV-1 needs to fuse its lipid bilayer with the plasma 
membrane of the host cells to deliver the components of the viral particle into the 
host cytoplasm. Subunits of the envelope (Env) glycoprotein mediate viral 
binding and membrane fusion. Env protein is produced as a precursor in the cell 
and subsequently cleaved to two subunits; gp120 and gp41 by a furin-like 
protease in the endoplasmic reticulum (26). The outer subunit gp120 is required 
for viral binding while the transmembrane subunit gp41 is required for membrane 
fusion. Binding of gp120 to the cellular receptor CD4 triggers a conformational 
change that enables interactions with one of the co-receptors; CCR5 or CXCR4 
(27-30). This is then followed by fusion and entry. Since cellular entry of HIV-1 is 
pH independent, for years it has been thought that viral fusion with the cellular 
membrane happened at the cell surface (31). However recent evidence obtained 
using single particle tracking and imaging technologies suggests that at least in 
some cell types viral fusion occurs at the endosomes (32). 
Following membrane fusion, contents of the viral particle are released into the 
cytoplasm. At this stage viral core which is composed of the capsid protein  
disassembles in a process called uncoating. Despite being a very important step, 
uncoating is one of the least characterized parts of the HIV-1 life cycle. Currently 
most of the controversy is centered on the precise timing and the cytoplasmic 
location of the  uncoating process (reviewed in (33-35)). While strong evidence 
obtained using capsid mutants indicate that uncoating is coupled to reverse 
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transcription (36-38), recent data from different studies is contradictory on 
whether reverse transcription process affects the kinetics of uncoating (39-42). 
Some evidence suggests that uncoating may be required for the host factors 
involved in the reverse transcription to access the reverse transcription complex 
(RTC) (43, 44). However whether the complete capsid disassembly is required 
for this or not is still not clearly established.  
 
Reverse transcription of retroviruses starts with the synthesis of minus strand 
strong stop sequence which is primed by a cellular tRNA that is packaged into 
the virus particle. Following a strand transfer event called first jump, minus strand 
synthesis is completed. The newly formed DNA/RNA hybrid is degraded through 
the action of viral RNase H. However 3' and central polypurine tracts can resist 
this degradation and serve as primers for the plus strand synthesis. Following 
another strand transfer called second jump, plus strand synthesis is completed 
and the final product of reverse transcription, double stranded DNA, is formed 
(Figure 1-4). At this point the complex of host and viral proteins that surround the 
viral DNA is called pre-integration complex (PIC). In some retroviruses such as 
HIV-1 this complex is actively imported into the nucleus and the viral DNA is 
integrated into host chromosome through the action of viral integrase (45). 
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Late phase 
Viral DNA that is integrated into the host genome is called provirus. This provirus 
uses the cellular transcription machinery, specifically RNA polymerase II, to 
synthesize the viral mRNAs. Some of these are spliced or unspliced and used as 
a template for translation of viral proteins such as Gag, GagPol and Env and the 
accessory factors discussed above. Full length unspliced viral RNA is packaged 
into the newly formed virions. Each virion contains 2 copies of this RNA. The 
core genes of the virus Gag, GagPol and Env are produced as polyproteins in 
the host cell. Envelope protein gets post-translationally cleaved by a cellular 
protease and glycosylated in the endoplasmic reticulum (26). Assembly of Gag 
and GagPol on the plasma membrane is achieved through the myristoylated N-
terminus of Gag which is inserted into the lipid bilayer of the cell membrane (46, 
47). Cleavage of Gag and GagPol into the final products is catalyzed by the viral 
protease which is part of the Pol (Figure 1-5). This process is called maturation 
and it doesn't start until the virus budding process is initiated (48).  
 
Host Cell Factors 
Same as other viruses from various different families, HIV-1 is an obligate 
intracellular parasite. Since the HIV-1 genome only encodes for 15 proteins, 
successful completion of the viral life cycle requires complex interactions with 
various host cell factors at each stage of the replication cycle. Besides the host 
factors that are used by the virus (known as cofactors), cellular innate immune 
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system also expresses many proteins to inhibit viral replication. These are 
collectively called restriction factors. With the publication of several genomewide 
RNAi screens that examine HIV-1 replication in recent years the number of host 
cell factors involved in HIV-1 infection has increased substantially (49-51). 
However the role of most of these candidate genes in HIV-1 infection remain to 
be confirmed. For this reason in this part of the dissertation I will describe the 
major host cell factors which have been studied extensively so far in HIV-1 
replication cycle.  
 
Cofactors 
Viral Entry 
 
CD4 
The First cofactor of HIV-1 replication to be identified was the main receptor of 
the virus, CD4. In the initial days of the HIV/AIDS epidemic it became clear that 
the immunodeficiency in the patients was primarily caused by the depletion of 
CD4 positive T cells (1, 2). Soon after the discovery of HIV-1 as the causative 
agent of AIDS selective targeting and killing of the CD4 but not CD8 positive T 
cells by the virus was shown in vitro (52, 53). In addition, monoclonal antibodies 
against CD4 were demonstrated to inhibit the replication of HIV-1 in cell culture 
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(27, 54, 55). These observations together with the fact that successful replication 
of HIV-1 in B cells following transfection of CD4 led to the conclusion that CD4 
acts as the receptor of HIV-1 entry (27, 54). CD4 was also the first retroviral 
receptor to be identified. CD4 belongs to the immunoglobulin superfamily of 
transmembrane proteins and has an important role in activation of the T cell 
receptor mediated signaling pathway through antigen presentation by MHCII 
(56).   
 
CXCR4 and CCR5 
Despite the initial suspicions that CD4 may not be the only receptor for HIV-1 
entry, it took about 10 years for the co-receptors of HIV-1 to be identified. Early 
studies from multiple groups reported isolation of viruses with differential 
infectivity in different cell types (57, 58). Some isolates that were found in 
patients who didn't develop AIDS were found to not to be capable of replicating in 
certain T cell lines while isolates from patients with severe immunodeficiency 
could easily infect these cells (58). These results led to classification of viral 
isolates based on their target cell preference as T cell tropic and macrophage 
tropic. The reason for this difference finally became clear with the identification of 
co-receptors of HIV-1. First co-receptor was identified using a cell-cell fusion 
assay between cells that express HIV-1 gp120 and another expressing CD4 and 
transduced with pools of a cDNA library. Using this assay the chemokine 
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receptor CXCR4 (initially called fusin) was identified as the co-receptor of HIV-1 
(30). Within a couple of months of the publication of this study another 
chemokine receptor, CCR5, was identified as a co-receptor of HIV-1 by multiple 
different groups (28, 29). These studies used the previous observation that beta 
chemokines RANTES, MIP-1alpha and MIP-1beta inhibited infection of 
macrophage tropic HIV-1 isolates as the starting point and showed that 
exogenous expression of the common receptor for these chemokines, CCR5, 
can make CD4 expressing non-permissive cells infectable by macrophage tropic 
HIV-1 (28, 29). This discovery quickly led to solving of an interesting puzzle in 
HIV field. Partners of some HIV-1 infected patients had been observed to be 
resistant to infection by HIV-1 (59, 60). Analysis of peripheral blood mononuclear 
cells from two such resistant patients revealed a 32 bp deletion in the gene 
encoding for CCR5 leading to lack of CCR5 on the cell surface (61). This allele is 
commonly found in northern European populations, and in the homozygous state 
can render a person resistant to HIV-1 infection (62). In fact an HIV-1 infected 
person who had developed an unrelated leukemia became virus free following a 
bone marrow transplant from a donor with the homozygous CCR5 delta 32 allele 
(63). Due to the success of this approach in effectively curing HIV infection, 
recent efforts have focused on targeted mutagenesis of CCR5 using site specific 
endonucleases such as Zinc Finger Nucleases (64, 65). 
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Reverse Transcription and Uncoating 
 
Cyclophillin A 
Cyclophillin A (CypA) is a peptidylprolyl isomerase which was initially discovered 
as a protein that binds to the immunosuppressive drug cyclosporin A (66). It was 
later identified as a binding partner of HIV-1 capsid in a yeast two hybrid screen 
(67). Initially it was suggested that CypA affected HIV-1 replication through its 
incorporation into virus particle in the producer cells (68). It was later found that 
CypA plays an important role in the early phase of the particle whether it is found 
in the producer cells or not (69). CypA binds to the viral capsid involving amino 
acid residues G89 and P90 and catalyzes the isomerization of the peptide bond 
between these residues (70, 71). It is not clear what effect does this 
isomerization have on the viral capsid core. Despite more than 20 years of 
research precise mechanism of action of CypA in viral replication is unknown. 
Inhibition of capsid-CypA binding by mutagenesis or through competitive 
inhibition via cyclosporine A decreases the accumulation of viral reverse 
transcription products (72, 73). This indicates that CypA impacts early steps in 
viral replication such as uncoating or reverse transcription. Multiple models for 
this action have been proposed. While one model suggests that binding of CypA 
destabilizes the capsid core promoting the uncoating process, another model 
suggests that CypA may stabilize the core in low concentrations, while help 
destabilize it in high concentrations (69, 74-76). 
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Other factors 
Another peptidylprolyl isomerase that is implicated in HIV-1 uncoating is Pin1 
(Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) (77). Pin1 has recently 
been show to be required for HIV-1 uncoating possibly through its interaction with 
the phosphorylated viral capsid core (78).  
 
Several host factors with roles in HIV-1 reverse transcription process were 
identified in the last three decades. Examples of this include survival motor 
neuron interacting protein 1 (also called Gemin2) which is an integrase binding 
protein that can enhance reverse  transcription (79, 80), DNA topoisomerase 1 
(TOP1) which interacts directly with NC and increases HIV-1 cDNA synthesis 
efficiency (81) and tRNA(Lys3) which is packaged into the virions and acts as the 
primer of reverse transcription (82, 83).  
 
Nuclear Import 
 
TNPO3 
TNPO3 (transportin 3) is a beta karyopherin that mediates nuclear transport of 
serine arginine rich proteins in the cell in a RanGTP dependent manner (84). The 
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role of TNPO3 in HIV-1 life cycle was discovered during a yeast two hybrid 
screen of integrase interacting host factors (85). In the same study it was also 
demonstrated that depletion of TNPO3 from the cells via RNAi led to a defect in 
nuclear entry of the PIC. TNPO3 was also found as an HIV-1 cofactor in two of 
the genomewide RNAi screens performed recently (49, 50). Later studies 
showed that knockdown of TNPO3 leads to a change in integration sites of HIV-1 
provirus (86). Interest in TNPO3 has increased recently when multiple groups 
demonstrated the importance of capsid in the function of TNPO3 in the HIV-1 life 
cycle (87-89). Now biochemical evidence exists for capsid binding to TNPO3 
(88). Despite all this, the exact mechanism of action of TNPO3 mediated nuclear 
import of HIV-1 PIC remains to be discovered. 
 
Nucleoporins 
Similar to TNPO3 two members of the nucleoporin family were identified in two of 
the genomewide RNAi screens for HIV-1 host factors; Nup153 and Nup358 (also 
known as RANBP2) (49, 50). Members of this family form the building blocks of 
the nuclear pore complex. Nup153 is found on the nuclear side of the pore 
complex while Nup358 forms the cytoplasmic filaments of the nuclear pore 
complex (90, 91). Like TNPO3, depletion of these proteins from the cell via RNAi 
decreases the accumulation of 2LTR circles in the nucleus indicating a defect in 
the nuclear import of viral PIC (87). Moreover both Nup153 and Nup358 were 
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found to be interacting with HIV-1 capsid protein (92, 93). A recent study 
suggests that Nup358 may be used in docking of PIC to the nuclear pore through 
its interaction with the capsid (94). The location of Nup153 in the nuclear pore 
suggests that it may be involved in the exit of the PIC from the nuclear pore 
complex to the nucleus.  
 
Integration 
 
LEDGF/p75 
Lens Epithelium-derived Growth factor (LEDGF/p75) is transcriptional co-
activator that is a member of the HRP (hepatoma-derived growth factor related 
protein) family (95). It is one of the two proteins encoded by a gene called PSIP1 
(96). The involvement of LEDGF/p75 in HIV-1 life cycle was implicated when it 
was discovered as an integrase binding partner in a co-immunoprecipitation 
assay from 293T cells that were engineered to ectopically overexpress HIV-1 
integrase (97). Initial loss of function experiments failed to identify the function of 
LEDGF/p75 in HIV-1 life cycle (98). It was later found that complete or almost 
complete knockdown of LEDGF/p75 is required to see a substantial enough 
effect in viral infection due to the fact that intracellular levels of this protein 
represent only a fraction of the levels required for its role in viral integration (99). 
Several studies over the years have accumulated evidence for the current model 
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of the role of LEDGF/p75 in HIV-1 integration. According to this model 
LEDGF/p75 functions as a molecular tether between HIV-1 integrase and 
transcriptionally active chromosomal sites directing the proviral integration to 
these sites (99-101). Some evidence also suggests that loss of this interaction 
leads to a decrease in the steady state levels of integrase indicating a role of 
LEDGF/p75 in stability of integrase (98). Since integration of HIV-1 provirus still 
happens, albeit at low levels, in the complete absence of LEDGF/p75, it is 
possible that other factors are involved in directing the viral DNA integration into 
the host chromosome. 
 
BAF 
Barrier to autointegration factor (BAF) was discovered as a part of PIC of another 
retrovirus called MLV (Murine Leukemia Virus) that prevented viral double 
stranded DNA to integrate into itself (also known as autointegration) (102). 
Endogenous function of this protein remains unknown. The same mechanism of 
autointegration prevention was later found in HIV-1 PICs as well (103, 104). 
According to these studies BAF acts as a dimeric bridge that can bind to and 
compact viral DNA in a sequence independent manner to prevent 
autointegration.   
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Transcription and mRNA export 
 
Cyclin T1 
Once integrated into the host chromosome, expression of HIV-1 mRNAs is driven 
by the 5' LTR. HIV-1 LTR contains a core promoter region with TATA box and 
multiple Sp1 transcription binding sites as well as an enhancer region slightly 
upstream of this core promoter which has binding sites for transcription factor 
NFkB (105, 106). Early studies of HIV-1 transcripts had shown that in the 
absence of the viral accessory factor Tat only short abortive transcripts are found 
in the cell while addition of Tat leads to the production of full length viral mRNA 
(107). This abortive transcription is thought to be caused by a stem loop structure 
in the viral mRNA called TAR (Trans activating response) (108). This structure is 
bound by negative elongation factor (NELF) leading to stalling of RNA 
polymerase II (109). The mechanism of Tat mediated removal of this block 
became clear when a member of the transcriptional elongation complex (P-
TEFb) called Cyclin T1 was identified as a Tat binding partner (21). According to 
the current model, Tat binds to TAR through its RNA binding domain and recruits 
P-TEFb to the promoter region through its interaction with Cyclin T1. This leads 
to phosphorylation of C terminal domain of RNA polymerase II and elongation of 
viral transcripts. 
19 
 
CRM1 
Formation of nuclear export competent mRNPs (messenger ribonucleoprotein 
particles) requires coordination of a complex series of processing events which 
are also tightly coupled to transcription. This presents a significant challenge for 
some viruses such as HIV-1 that produce unspliced, intron containing mRNAs. 
HIV-1 gets around this block by using one of its accessory factors Rev that 
enables the export of its unspliced mRNAs. Rev binds the viral mRNA through a 
region with complex secondary structure called RRE (rev response element) that 
is found in the env gene coding sequence (22, 110). Nuclear export of Rev 
bound viral mRNA is achieved by the recruitment of the export complex; CRM1 
and RanGTP through nuclear export signal found on the Rev protein. This 
complex is transported through the nuclear pore complex into the cytoplasm. In 
the cytoplasm Ran GTPase-activating protein 1 hydrolyzes the Ran-associated 
GTP into GDP which leads to dissociation of Rev and the viral mRNA from the 
export complex (111-114). 
 
Assembly and Budding 
 
TSG101 and the ESCRT Complex 
Studies in early 90s demonstrated that mutations in the p6 protein of HIV-1 that 
is found at the C terminus of Gag polyprotein lead to a defect at a late stage in 
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the viral budding process (115). Since HIV-1 is an enveloped virus, budding of 
the viral particles requires severing and resealing of the connection between the 
viral membrane and the plasma membrane. The mutations in p6 that were later 
mapped to the PTAP domain (also called late budding domain) led to an 
inhibition of the membrane breakage at the end of the budding process and 
hence accumulation of immature viral particles that are attached to the cell (116). 
About a decade after the discovery of the importance of p6 in HIV-1 particle 
budding, one of the cellular components of this process was revealed with the 
identification of TSG101 (Tumor susceptibility gene 101) as a binding partner of 
HIV-1 p6 in a yeast two hybrid screen (117). TSG101 is an inactive homologue of 
ubiquitin conjugating enzymes (E2) which are normally involved in transferring 
activated ubiquitin to E3 ligases for ubiquitin post-translational modification (118). 
TSG101 is involved in sorting of endosomal proteins into multivesicular bodies 
(MVBs) through its interactions with the ESCRT (The endosomal sorting 
complexes required for transport) machinery (119). In addition to the endosomal 
protein sorting, ESCRT machinery has been shown to have an important role in 
the scission of the membranous stalk that connects the two cells at the end of the 
cell division (120). It is thought that HIV-1 recruits the ESCRT machinery through 
the interaction of p6 with TSG101 and hijacks the function of this complex in 
MVB formation to form the membranous curvature at the plasma membrane and 
exit the cell following membrane scission which is again provided by the ESCRT 
machinery (reviewed in (121)). 
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Restriction Factors 
 
TRIM5α 
The existence of restriction factors of retrovirus replications were postulated in 
the late 60s while studying tumor induction in mice by MLV when it was observed 
that certain isolates of this virus were able to replicate only in certain strains of 
mice (122). Due to this inhibition, MLV strains were classified according to their 
ability to infect NIH (N-MLV) or Balb/c (B-MLV) mice (123). The dominant 
restriction factor, Fv1 (Friend virus susceptibility factor-1) was later found to be 
acting on the capsid protein of MLV leading to an inhibition after reverse 
transcription but before integration (124). The gene causing this inhibition was 
cloned in the mid 90s by positional cloning (125). It is found to be encoding a 
Gag-like protein of a mouse endogenous retrovirus (125). Even though Fv1 was 
only found in mice, a similarly dominant and capsid associated restriction of N-
MLV was later reported in some human cells. The factor causing this restriction 
was named Ref1 (restriction factor 1) at the time (126). In addition, another Fv1-
like restriction was observed when HIV-1 and SIV were used to infect several 
cells from different non-human primates (127, 128). For example HIV-1 infection 
was blocked in rhesus macaque cells while SIV infection was blocked in squirrel 
monkey cells (128). Similar to Ref1 and Fv-1, this restriction factor (named Lv1) 
was dominant and sensitivity of viruses could be mapped to the capsid protein 
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(128, 129). In 2004, TRIM5α was identified as the gene encoding the HIV-1 
restriction factor in rhesus macaque cells by transferring a cDNA library made 
from rhesus macaque lung fibroblasts to Hela cells and selecting the cells 
resistant to infection by HIV-1 but not SIV (130). Not long after the discovery of 
TRIM5α, several groups demonstrated that Ref1 and Lv1 were species specific 
versions of TRIM5α (131, 132). 
TRIM5α belongs to the TRIM (Tripartite motif) family of proteins which are 
characterized by the presence of three motifs in each member named RING, B-
Box and coiled-coil (133). In addition to these motifs, TRIM5α also contains a C 
terminal domain called B30.2 or SPRY. Rapid evolution of some of the residues 
found in this domain suggested the importance of this domain in the interaction of 
TRIM5α with the virus which was later found to be through the capsid protein 
(134-137). Interestingly in the genome of some non-human primate species such 
as owl monkeys SPRY domain of TRIM5 is replaced by another capsid binding 
gene Cyclophillin A. The resulting fusion protein is named TRIM-Cyp (132).  
Despite numerous studies conducted to understand how TRIM5α inhibits 
retroviral infection, the exact mechanism of restriction is still unknown. Initial 
evidence suggested a model involving the binding of TRIM5α to the incoming 
viral capsid leading to acceleration of the uncoating process through proteasomal 
degradation and eventually inhibition of reverse transcription. Supporting this 
model is the E3 ubiquitin ligase activity associated with the RING domain of 
TRIM5α (138, 139). However addition of a proteasome inhibitor doesn't relieve 
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the inhibition of viral infectivity even though it allows the completion of reverse 
transcription (140). This indicates that neither proteasomal degradation of 
incoming capsids nor the inhibition of reverse transcription is required for the 
anti-retroviral activity of TRIM5α. While it is still not clearly established how 
TRIM5α inhibits the post reverse transcription steps, evidence has emerged from 
recent studies suggesting that TRIM5α acts as pattern recognition receptor which 
signals to innate immune pathways in the cell following recognition of the higher 
order capsid lattice of the virus (141, 142). Interestingly this signaling pathway 
has been shown for in some of the other human TRIM proteins as well (143).  
 
APOBEC3G 
Multiple studies of HIV-1 infections in late 80s and early 90s showed that viruses 
deficient in one of the accessory factors, Vif, didn't grow in some human T cell 
lines such as CEM and Hut78 while they were able to replicate efficiently in 
others such as Cem-SS and SupT1 (144-146). Due to this discrepancy, cells that 
didn't support infection with Vif deficient HIV-1 were called non-permissive while 
the ones that supported the infection were called permissive. Initial studies as 
well as some later ones have also indicated that this effect was in the producer 
cells since Vif deficient viruses made in permissive cells were able to infect both 
permissive and non-permissive cells (147, 148). Presence of an inhibitory factor 
in the non-permissive cells was confirmed by the dominant non-permissive 
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phenotype of the heterokaryons generated from fusion of permissive and non-
permissive cells (147, 148). The restriction factor was later identified using a 
cDNA subtraction library approach. In this study to increase the chance of finding 
the gene specific to non-permissive cells authors used two T cell lines; one 
permissive and the other non-permissive. This analysis led to identification of 
APOBEC3G (apolipoprotein B mRNA-editing catalytic polypeptide-like 3G) as the 
restriction factor in the non-permissive cells that is targeted by Vif (23). In the 
same study it was also found that APOBEC3G is packaged into virions, hence 
explaining why non-permissive cells were infectable with virus produced in 
permissive cells (23). 
APOBEC3G belongs to a subfamily of cytidine deaminases which get their 
namesake from the function of APOBEC1 which was the first member of this 
family to be identified (149). This family is characterized by the presence of one 
or two Zinc binding deaminase domains in each member. Soon after its 
identification it was shown that virion packaged APOBEC3G catalyzed the 
deamination of cytosine to uracil during minus strand synthesis of viral reverse 
transcription (150). This leads to the accumulation of G to A mutations during 
plus strand synthesis. This massive hypermutation is thought to be the reason for 
the inhibition of the replication of Vif deficient viruses. 
In addition to HIV-1, APOBEC3G and some members of the APOBEC3 family 
have been shown to mediate restriction of several other retroviruses ranging from 
SIV to human foamy virus as well as endogenous retroelements including Alu 
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and human endogenous retroviruses (151-155). While HIV-1 and some 
lentiviruses utilize vif to target APOBEC3 proteins for degradation, other 
retroviruses such as HTLV and MLV seems to exclude encapsidation of these 
APOBEC proteins (156). Vif mediated degradation of APOBEC3G has been 
shown to be achieved by adaptor action of vif between APOBEC3G and a E3 
ubiquitin ligase complex leading to polyubiquitination and subsequent 
degradation of APOBEC3G by the 26S proteasome (157). Recent evidence 
indicates the requirement of a transcription factor called CBFβ in this process 
(158). 
 
Tetherin 
Similar to vif, early studies of HIV-1 replication demonstrated that there was a 
substantial decrease in the amount of virus produced in certain cell types in the 
absence of the accessory protein vpu (159, 160). Electron microscopy of the 
non-permissive cells infected with vpu deficient viruses showed that the particles 
were unable to detach from the surface of the cells (160). This phenotype was 
subsequently shown to be dominant in  heterokaryons made from fusions of non-
permissive and permissive cells (161). Later it was found that this phenotype was 
caused by an IFNα (Interferon alpha) inducible factor and addition of HIV-1 vpu 
counteracted the tethering of viral particles to the cell surface (162, 163). 
Therefore unlike in the case APOBEC3G, permissive cells can be made non-
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permissive by the addition of IFNα. Using the information accumulated on this 
restriction factor over the years Neil et al. used microarray analysis from several 
different cell lines to identify candidate genes. Among these IFNα inducible 
transmembrane protein Tetherin (also called BST-2 or CD317) fulfilled all the 
criteria and was identified as the restriction factor blocking the release of HIV-1 
particles in the absence of vpu (20). It was subsequently shown that in the 
presence of vpu Tetherin is downregulated from the cell surface (164).  
Tetherin is a single pass transmembrane protein which has an N-terminal 
cytoplasmic domain followed by a transmembrane domain and a C-terminal 
extracellular domain with a glycosylphosphatidylinositol anchor at the end (165). 
Due to the presence of double membrane anchors in its topology, Tetherin has 
been shown to inhibit budding of a variety of other enveloped viruses in addition 
to retroviruses (166-169). In addition to vpu of HIV-1 and some SIVs other 
viruses have evolved different mechanisms of counteracting the effects Tetherin. 
For example, Ebola virus glycoprotein as well as the envelope proteins of HIV-2 
and FIV can antagonize antiviral activity of Tetherin (170-172). Mechanism of the 
downregulation of Tetherin by vpu has gotten clearer over the years. The current 
model includes recruitment of βTrCP2 (β-transducin repeat-containing protein 2), 
which is a member of an E3 ubiquitin ligase complex, by vpu following its direct 
interaction with the cytoplasmic domain of Tetherin. This leads to ubiquitination of 
Tetherin (non-lysine) which signals to the HRS (hepatocyte growth factor-
regulated tyrosine kinase substrate) component of the ESCRT complex leading 
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to trafficking and degradation of Tetherin in the lysosomal compartment (173-
176). In addition to the degradation of Tetherin, other studies have shown that 
vpu can sequester Tetherin by either trapping it in the Trans Golgi network or 
blocking its recycling to the cell membrane (177, 178). It is possible that these 
antagonistic effects of vpu act in concert to counteract the antiviral activity of 
Tetherin as opposed to being mutually exclusive. 
 
SAMHD1 
Low level infectivity of monocyte derived macrophages and dendritic cells by HIV 
was observed in the early days of HIV research (179). Interestingly this inhibition 
can be overcome by first infecting the cells with virus like particles containing 
accessory protein Vpx found in HIV-2 and SIVsm (180, 181). Similar to its 
counterpart in HIV-1, Vpr, Vpx interacts with the DDB1–CUL4–DCAF E3 ligase 
complex (182). This interaction was shown to be required for the increase in viral 
infection observed in myeloid cells after the addition of Vpx (183). Since this E3 
ligase complex is involved in ubiquitin mediated proteolytic degradation of 
targeted proteins, Vpx was suggested to counteract the antiviral activity of a 
restriction factor by degradation in myeloid cells (180). This factor was later 
identified as SAMHD1 (SAM domain and HD domain-containing protein 1) using 
affinity purification of Vpx interacting proteins in non-permissive cells followed by 
mass spectrometry (184, 185).  
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Soon after the identification of SAMHD1 as the HIV-1 restriction factor in myeloid 
cells, its mechanism of action became clear. SAMHD1 contains a C terminal 
nucleotide phosphohydrolase domain which suggested that it could have a 
function in nucleotide metabolism (186). Multiple studies have now shown that 
SAMHD1 works as a deoxynucleotide triphosphohydrolase (187-189). It restricts 
replication of HIV-1 by depleting the intracellular dNTP pool. Since non-dividing 
cells such as monocyte derived macrophages don't require DNA replication, they 
contain low intracellular dNTP levels. By decreasing the dNTP concentration in 
these cells SAMHD1 blocks HIV-1 reverse transcription (188). Even though Vpr 
of HIV-1 cannot antagonize SAMHD1, Vpr from some of the SIV strains can 
degrade SAMHD1 (190). This suggests that HIV-1 may have evolved to avoid 
replicating in myeloid cells possibly to escape from an antiviral signal. 
 
Over 30 years of research led to the identification of dozens of host cell factors 
that have various roles in HIV-1 life cycle as reviewed above. However recent 
genomewide studies have shown that we still only have a fraction of the whole 
picture. Hence more in depth studies are required to understand how HIV-1 
interacts with the host cell. The goal of this dissertation is to understand the role 
of host cell factors in the life cycle of HIV-1. I decided to approach this in two 
parts: In the first two parts I investigated a cellular pathway that was implicated to 
have a role in retroviral life cycle but never studied in the context of HIV-1 
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infection. In the last part I studied a block to infection by retroviruses and 
retroviral vectors in human myeloid cell line. 
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Figure 1-1. Schematic representation of HIV-1 viral particle.  
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Figure 1-2. HIV-1 Genome. Diagram of proviral DNA of HIV-1 with encoded 
genes.  
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Figure 1-3. HIV-1 Replication Cycle. Step 1. Binding; HIV-1 particle binds CD4 
and one of the co-receptors CCR5 or CXCR4 on the cell surface through surface 
envelope protein gp120. Step 2 and 3. Virion fusion happens with the action of 
transmembrane protein gp41 and contents of the particle are released into the 
cytoplasm. Step 4. Viral capsid core is disassembled in the uncoating process. 
Step 5. viral RNA genome is reverse transcribed to double stranded DNA with 
the action of reverse transcriptase. Step 6. Pre-Integration complex that contains 
viral cDNA, several viral and cellular proteins gets imported into the nucleus Step 
7. Viral double stranded DNA gets integrated into the host chromosome. Step 8 
and 9. Viral RNAs are transcribed and exported into the cytoplasm. Step 10. 
Viral polyproteins and accessory are produced. Step 11. Viral proteins assemble 
at the plasma membrane and the virus buds out of the cell. Step 12. Viral 
polyproteins are cleaved by the viral protease and the mature particle is formed. 
Major restriction factors and the part of the life cycle they inhibit are indicated. 
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Figure 1-4. HIV-1 reverse transcription process. 1. Reverse transcription 
starts with the binding of tRNA that is packaged into the virus particle at the 
primer binding site (PBS). 2. Minus strand synthesis is initiated and continues 
until it reaches to the 5' end of the viral RNA. This is  called strong stop DNA. 3. 
RNA strand of this DNA/RNA hybrid is degraded by viral RNase H. 4. First strand 
transfer (also called first jump) occurs through the homology of the R region at 
the LTR. 5. Minus strand synthesis resumes after the first jump. 6. RNA strand of 
the newly formed RNA/DNA hybrid is degraded by RNase H. Two sets of 
polypurine tracts (PPT) called 3' PPT and central PPT (cPPT) are relatively 
resistant to this degradation and remain intact. 7. Plus strand synthesis is primed 
at the PPTs. Synthesis of plus strand stops after a part of the tRNA is reverse 
transcribed generating the PBS. 8. Following RNase H mediated degradation of 
the tRNA primer and the 3' PPT, second strand transfer occurs (also called 
second jump) with the annealing of PBS regions from the plus strand and the 
minus strand. 9. Synthesis of both strands is completed leading to the formation 
of the viral cDNA. 
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Figure 1-5. Schematic representation of Gag and GagPol processing by 
HIV-1 protease. Protease cleavage sites at Gag and GagPol polyprotein are 
indicated by arrows. Mature forms of viral proteins that make up Gag and GagPol 
are shown at the bottom of the figure. 
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Class of Drug  Mode of Action  List of FDA approved drugs  
Nucleoside/Nucleotide 
Analog Reverse 
Transcriptase Inhibitors  
Inhibit viral reverse 
transcription by competing with 
the incorporation of nucleotides 
to the growing viral cDNA 
chain.  
Emtricitabine, lamivudine, 
zalcitabine, zidovudine, 
stavudine, Didanosine, 
Tenofovir, abacavir  
Non-Nucleoside Reverse 
Transcriptase Inhibitors  
Inhibit the action of viral 
reverse transcriptase by 
directly binding to the enzyme  
Rilpivirine, etravirine, 
delavirdine, efavirenz, 
nevirapine  
Protease Inhibitors  Prevent formation of mature 
viral particles by directly 
binding and inhibiting the action 
viral protease 
Amprenavir, tipranavir, 
indinavir, saquinavir, 
ritonavir, darunavir, 
atazanavir sulfate, nelfinavir 
mesylate  
Integrase Inhibitors  Inhibits integration of viral 
cDNA into the host 
chromosome by directly 
binding and inhibiting viral 
integrase  
Raltegravir, dolutegravir  
Entry/Fusion Inhibitors  Inhibit viral binding and fusion 
either by binding to viral gp41 
(enfuvirtide) or cellular CCR5 
(maraviroc)  
Enfuvirtide, maraviroc  
 
Table 1-1. List of FDA approved antiretrovirals and their mode of action.  
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The N-end Rule and Retroviral 
Infection: No Effect on Integrase 
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Summary 
Integration of double stranded viral DNA is a key step in the retroviral life cycle. 
Virally encoded enzyme, integrase, plays a central role in this reaction. Mature 
forms of integrase of several retroviruses (i.e. HIV-1 and MLV) bear conserved 
destabilizing N-terminal residues of the N-end rule pathway - a ubiquitin 
dependent proteolytic system in which the N-terminal residue of a protein 
determines its half life. Substrates of the N-end rule pathway are recognized by 
E3 ubiquitin ligases called N-recognins. We have previously shown that the 
inactivation of three of these N-recognins, namely UBR1, UBR2 and UBR4 in 
mouse embryonic fibroblasts (MEFs) leads to increased stability of ectopically 
expressed HIV-1 integrase. These findings have prompted us to investigate the 
involvement of the N-end rule pathway in the HIV-1 life cycle. 
Our results showed that infectivity of HIV-1 but not MLV was decreased in N-
recognin deficient cells in which three N-recognins (UBR1, UBR2 and UBR4) 
were depleted. HIV-1 integrase mutants of N-terminal amino acids (coding for 
stabilizing or destabilizing residues) were severely impaired in their infectivity in 
both human and mouse cells. Quantitative PCR analysis revealed that this 
inhibition was mainly caused by a defect in reverse transcription. The decreased 
infectivity was independent of the N-end rule since cells deficient in N-recognins 
were equally refractory to infection by the integrase mutants. MLV integrase 
mutants showed no difference in their infectivity or intravirion processing of 
integrase.  
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In conclusion the N-end rule pathway impacts the early phase of the HIV-1 life 
cycle; however this effect is not the result of the direct action of the N-end rule 
pathway on the viral integrase. The N-terminal amino acid residue of integrase is 
highly conserved and cannot be altered without causing a substantial decrease in 
viral infectivity. 
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Introduction 
Retroviruses are obligate intracellular parasites that must exploit host cell 
pathways during their life cycle. These activities range from using motor proteins 
(191), nuclear import (192) and export pathways, to transcription (21) and 
processing (193) of the viral genome. Studying the role of these cellular 
pathways in retroviral replication can lead to a deeper understanding of the viral 
life cycle. This has been highlighted recently with the development of high 
throughput screening techniques which have implicated numerous proteins that 
are either required or act to restrict retroviral infection (49-51, 194). One of the 
processes repeatedly implicated in several genome wide screens is the ubiquitin 
proteasome pathway that mediates signal dependent degradation of proteins. 
Different proteins of this pathway have been found in all four genome wide RNAi 
screens conducted looking for host factors used by HIV-1 (49-51, 194). Although 
over the years, a variety of studies have implicated the ubiquitin proteasome 
system in the viral life cycle, research on the role of this essential pathway in 
retroviral infection has mostly focused on targeting of cellular restriction factors to 
the proteasome by viral accessory proteins (184, 195, 196). Results of the 
genomewide studies on host factors suggest that retroviruses may be using the 
ubiquitin proteasome pathway in the early phase of the viral life cycle. 
 
One of the degradation signals that target cellular proteins to the proteasome is 
the N-terminal amino acid residue of the protein. First described by Alex 
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Varshavsky and colleagues in 1986, this N-end rule is an ubiquitin dependent 
proteolytic system in which the identity of the N-terminal amino acid residue of a 
protein determines its half life in the cell (197). Even though it was originally 
discovered while expressing a bacterial protein in yeast cells the N-end rule 
pathway was subsequently found to be present in all organisms examined 
including mammals (198), plants (199), and bacteria (200). Hence it is an 
evolutionarily ancient mechanism for protein degradation. In mammalian cells, 
amino acids are classified as stabilizing (Met, Ala, Val, Gly, Pro, Ser, Thr) or 
destabilizing (Glu, Gln, Cys, Asp, Asn, Arg, Lys, His, Leu, Ile, Phe, Trp, Tyr) 
based on their ability to act as a degradation signal for the N-end rule pathway. 
Although the N-end rule classifies amino acids as destabilizing for the 
mammalian cells, it has been difficult to identify the cellular substrates of this 
pathway. However with the discovery of several signaling components of the N-
end rule pathway our understanding of this process has increased in the last 
decade. 
 
Specificity of the ubiquitin proteasome system is governed by E3 ubiquitin ligases 
that recognize a degradation signal on the target protein and catalyze the 
addition of ubiquitin onto the protein. For the N-end rule pathway, these ligases 
are called N-recognins, and the signal for degradation is termed an N-degron 
(201). The first N-recognin was discovered in S. cerevisiae and termed Ubr1 
(201). While Ubr1 is the sole N-recognin in yeast cells, subsequent studies have 
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identified two homologs of Ubr1 in mammalian genomes, UBR1 and UBR2 (202). 
These proteins have been shown to have highly similar sequences and 
overlapping functions (202, 203). Biochemical studies identified two more E3 
ligases that can bind to destabilizing N-terminal residues, termed UBR4 and 
UBR5 (203). These proteins contain a common zinc finger like domain termed a 
UBR box (203). Mammalian genomes contain three additional genes that code 
for the UBR box domain, UBR3, UBR6 and UBR7 (203). However these proteins 
have not been shown to bind any of the destabilizing residues and therefore their 
role in the N-end rule pathway, if any, is unknown.  
 
While recent studies on N-recognins have substantially increased our 
understanding of the N-end rule pathway, identification of the cellular substrates 
of N-end rule has been challenging. Since almost all mammalian proteins are 
synthesized with an N-terminal methionine, a stabilizing residue, an N-degron 
can only be created through post translational modifications, such as the removal 
of the N-terminal methionine (204) or endoproteolytic cleavage. Proteolytic 
cleavage of certain viral proteins can generate potential substrates for the N-end 
rule pathway. One viral protein that has been studied with respect to the N-end 
rule is the integrase of HIV-1. Retroviral integrase is synthesized as a part of a 
GagPol polyprotein (Pol in spumaretroviruses). Along with other viral proteins, 
GagPol is packaged into viral particle during assembly and, upon viral budding, 
the mature form of integrase is generated as a result of a series of proteolytic 
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cleavage events mediated by the viral protease. We have previously shown that 
concomitant impairment of three of the N-recognins that bind to destabilizing 
residues, UBR1, UBR2 and UBR4 in mouse embryonic fibroblasts (MEFs) leads 
to increased stability of ectopically expressed HIV-1 integrase bearing a 
destabilizing residue (203). These results and others (205, 206) raised the 
possibility that HIV-1 (and possibly other retroviruses) may utilize the N-end rule 
pathway to control the stability of integrase during viral infection. 
 
In this study we investigated the potential role of the N-end rule pathway during 
the early phase of the life cycle of two different retroviruses; HIV-1 and MLV. 
Here we show that HIV-1 but not MLV infectivity is decreased in cells where the 
N-end rule pathway was impaired. We also show that the N-terminal amino acid 
residue of HIV-1 integrase which has previously been suggested to be a target 
for degradation by the N-end rule is not targeted by the N-end rule pathway 
during infection. 
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Results 
 
Proteolytic cleavage of GagPol generates destabilizing N-end rule residues 
We first examined whether the cleavage of the GagPol polyprotein by HIV-1 
protease would generate mature proteins that expose destabilizing N-terminal 
residues of the N-end rule pathway. Each HIV-1 protease cleavage recognition 
site in the polyprotein between the subunits differs in its amino acid sequence. 
Hence the nature of the sequence and its accessibility is thought to determine 
the specificity for cleavage (207). Furthermore variation among groups or 
subtypes of HIV may result in sequence variation of the cleavage site. Therefore, 
we reasoned that if HIV-1 utilizes the N-end rule in its lifecycle, the N-terminal 
amino acids of mature protein should be conserved as N-degrons across 
different types, groups and subgroups of HIV-1. The conservation of N-terminal 
destabilizing residues across other lentiviruses would also suggest a selection 
pressure to maintain their interaction with N-end rule machinery. A previous 
study has compared HIV-1 type 1 protease cleavage sites and identified the most 
common recent common ancestor (MRCA) of protease cleavage sites in HIV-1 
for groups M, B and C (208). Of note, 7 proteins are expected to bear N-terminal 
destabilizing residues. We have further analyzed the conservation of the N-
terminal residues of these 7 proteins by comparing the sequences of 1850 HIV-1 
isolates from the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/). 
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Of the sequences analyzed we have found that 4 proteins (p1, Trans frame 
octapeptide (TFP), RNaseH and Integrase) have N-terminal amino acid 
sequences that are conserved relative to the MRCA. The data is summarized in 
Table 2-1 with respect to the N-terminal amino acid generated and its predicted 
behavior according to the N-end rule. Result for the cleavage site between 
Reverse Transcriptase and Integrase is shown in Figure 2-1. In this study we 
decided to focus on the integrase molecule because it was implicated as a target 
for the N-end rule (203, 205, 206) and since it is the focus of small molecule 
development to combat HIV-1. 
 
The N-end rule can impact HIV-1 infection. 
We tested if the N-end rule can impact HIV-1 infection. To this end we utilized 
single cycle HIV-1 reporter vectors and cell lines mutant in N-recognins. We have 
previously characterized redundant functions of the UBR proteins and hence 
generated cell lines singly or multiply mutant for UBR proteins (203). These are 
MEFs from UBR1-/-, UBR2-/- and UBR1-/- UBR2-/- strains of mice. We have 
also previously generated MEF lines that are deficient in all three UBR box 
proteins (UBR1, UBR2 and UBR4) that have been shown to bind type 2 
destabilizing residues by transducing UBR1-/- UBR2-/- cell lines with 3 different 
shRNAs against UBR4 mRNA (to account for any off target effects) and a shRNA 
targeting luciferase mRNA as a control. UBR4 knockdown was verified by 
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immunoblotting (203). Wild-type MEFs transduced with shRNA to UBR4 mRNA 
were used to investigate the effect of UBR4 knockdown alone. 
 
We infected N-recognin deficient MEFs with a HIV-1 EGFP vector pseudotyped 
with VSVG. Infectivity was reported as EGFP expression and was scored by flow 
cytometry 72hrs after infection. Figure 2-2 illustrates that the infectivity of HIV-1 
was unchanged over a range of MOIs (Multiplicity of Infection) comparing wild 
type (WT), MEFs for UBR1 -/-, UBR2 -/-, UBR4 KD, and the double deletion MEF 
UBR1 -/- UBR2 -/-. We observed a substantial decrease (5-6 fold) only in cells 
that are depleted in UBR1, UBR2 and UBR4.We confirmed that this decrease in 
infectivity is not due to a defect in the reporter or the expression of the reporter 
by using a different reporter (DS-Red) and a different promoter (CMV) (data not 
shown). 
 
HIV-1 infection is impaired at reverse transcription or uncoating in N-
recognin deficient cells. 
These results indicate that N-end rule pathway can impact the early phase of the 
HIV-1 life cycle. However decrease in infectivity by itself is not enough to 
determine whether the N-end rule acts on HIV-1 proteins or a cellular protein that 
is involved in infection. To better pinpoint the stage that is impaired we 
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determined which step in the viral life cycle is affected in the N-recognin deficient 
MEFs. Following infection we isolated total DNA from MEFs at different time 
points and tracked the relative accumulation of early reverse transcription 
products and 2LTR circles by qPCR. As shown in Figure 2-2 the infection in WT 
cells compared to UBR1-/- UBR2-/- cells are similar. Therefore we chose to 
compare UBR1-/- UBR2-/- LuciRNAi to UBR1-/- UBR2-/- UBR4RNAi cells.  As 
shown in Figure 2-3A, UBR1-/- UBR2-/- UBR4RNAi cells showed around 3-4 fold 
decrease in the accumulation of first jump products. Moreover the rate of 
increase in the accumulation of first jump products were found to be lower in the 
triply deficient cells especially in the early time points (compare 4 hour and 6 
hour time points) indicating a defect in reverse transcription. However the first 
point we analyzed also showed around 2 fold difference in the amount of first 
jump products between the control and the triply deficient cells, which suggests 
that another defect before the first jump step of the reverse transcription either at 
the start of reverse transcription or during the uncoating could contribute to this 
phenomenon. The difference we observed in the accumulation of reverse 
transcription products was further enhanced when we looked at the relative 
production of 2LTR circles. As illustrated in Figure 2-3B, the UBR1-/- UBR2-/- 
UBR4RNAi cells exhibited up to 7 fold less 2LTR circles compared to the control 
cells. However, since the 2LTR circles are only a subset of the reverse 
transcription products that enter the nucleus we do not observe any defect in 
nuclear import. Furthermore it has been reported that in the presence of mutant 
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non-functional integrase 2LTR circles are increased when compared to infection 
with wild type integrase (209, 210). Hence we compared the ratio of first jump to 
2LTR circles at 24 hrs. The data show that for UBR1-/- UBR2-/- UBR4RNAi 
Luciferase control cells the ratio is 216.7 ± 34.6, while the ratio in triply mutant 
cells is 250.3 ± 53.9. This indicates that the integrase function is not impaired in 
the triply mutant cells. We conclude that the triply deficient cells are impaired in 
early reverse transcription or uncoating. 
 
The N-end rule does not impact MLV infection. 
Similar to HIV-1,proteins of other retroviruses also harbor N-terminal residues 
that make them susceptible to the N-end rule. For example mature MLV 
integrase also bears a type 2 destabilizing residue isoleucine making it a 
potential substrate for the N-end rule pathway (211). A comparison of different 
retroviral integrase N-terminal residues revealed that all lentiviruses examined, 
gammaretroviruses and spumaretroviruses harbor destabilizing residues. 
However, this is not universal to retroviruses, since alpha, beta, delta and epsilon 
retroviruses harbor a stabilizing residue (Figure 2-4). To test whether MLV 
infection is affected by the impairment of the N-end rule pathway, we infected our 
N-recognin deficient MEFs using a MLV based EGFP vector pseudotyped with 
VSVG. In contrast to HIV-1, MLV infectivity was only slightly decreased in UBR1-
/- UBR2-/- UBR4KD cells compared to the other cells tested (Figure 2-5). Notably 
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the slight decrease was also present in the control UBR1 -/-, UBR2 -/-, Luciferase 
RNAi cell line. This leads us to conclude that the impact of the N-end rule on 
MLV infection is minimal. This also allows us to conclude that the decrease 
observed for HIV-1 on the triply deficient cells is not due to an entry defect since 
the MLV and HIV vectors are pseudotyped with VSVG and hence utilize the 
same mode of entry. 
 
The N-terminal residue impacts intravirion stability of integrase. 
The observed differential effect of N-recognin deficiency on HIV-1 and MLV 
prompted us to question the previous suggestions that HIV-1 integrase stability 
may be controlled by the N-end rule pathway during viral life cycle. To better 
assess the possible involvement of the N-end rule pathway in controlling 
integrase stability during retroviral infection, we generated N-terminal integrase 
point mutants of HIV-1 and MLV with an N-terminal stabilizing or destabilizing 
residue within the context of the GagPol protein (see Tables 2 and 3). For both 
viruses we chose methionine as the stabilizing residue since HIV-1 mutants with 
this residue at the N-terminus have previously been shown to produce virions 
(206). Both HIV-1 and MLV mature integrases bear a type 2 destabilizing residue 
at their N-terminus (211). Hence, we also substituted the WT destabilizing 
residues of both viruses with another, structurally similar type 2 destabilizing 
residue as an additional control. For HIV-1 we replaced phenylalanine at the N-
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terminus of integrase with another aromatic amino acid, tryptophan (Table 2-2). 
For the integrase of MLV, we replaced isoleucine with another branched chain 
amino acid, leucine (Table 2-3). In order to evaluate correct packaging and 
maturation of viral proteins in our integrase mutants, we analyzed viral pellets by 
immunoblotting. As shown in Figure 2-6A, HIV-1 integrase mutants successfully 
produced viral particles as evidenced by the presence of the mature capsid 
protein (p24) in the concentrated viral pellets. However, the amount of integrase 
was decreased in these mutants compared to WT virus. Levels of reverse 
transcriptase subunits found in the viral particles paralleled the decreased levels 
of integrase. In contrast levels of integrase were not significantly altered for the 
MLV integrase mutants (Figure 2-6B). 
 
HIV-1 Integrase mutants package equivalent amounts of GagPol. 
The observed reduction in the amount of integrase and reverse transcriptase 
suggested a possible defect in the processing of viral GagPol polyprotein. To 
better assess the effect of N-terminal residue integrase mutants of HIV-1 on viral 
proteolytic processing, we analyzed the intravirion accumulation of Gag, GagPol 
and other proteolytic processing intermediates. We generated WT and integrase 
mutant virions in the presence of increasing amounts of an HIV-1 protease 
inhibitor, ritonavir. On probing with a p24 antibody, WT and mutant virions 
showed similar patterns of processing intermediates indicated by the decrease in 
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the level of p24 and p32 followed by an increase in the level of higher molecular 
weight products such as p55 Gag and p160 GagPol as the concentration of 
ritonavir increased (Figure 2-7). Gag processing is unaffected by the integrase N-
terminal mutations as both WT and mutant virions showed identical patterns of 
cleavage intermediates (Figure 2-7, bottom). Virions produced at the highest 
concentrations of ritonavir (10μM) contained similar amounts of Gag and GagPol 
suggesting similar levels of packaging of these polyproteins into virions. Probing 
with an integrase antibody revealed similar processing intermediates p121 or 
p114 between wild-type and mutant virions (Figure 2-7, top).The larger 
proteolytic processing intermediates observed are consistent with previous 
studies and predictions based on the cleavage sites in the Gag and GagPol 
proteins (212, 213). We have observed an intermediate band between 40 and 50 
kDa that appears in the presence of suboptimal ritonavir concentrations. 
Although this fragment may indicate an alternative cleavage site induced by the 
mutation at the N terminal residue of Integrase, we have not observed the same 
fragment in separate virus batches produced in the absence of ritonavir (data not 
shown). Indeed separate experiments with ritonavir have revealed a similar 
fragment in suboptimal concentrations of ritonavir in both mutants and the WT 
virus (data not shown). Additionally we observe only slight differences in both 
infectivity and the amount of reverse transcriptase products in different batches 
of virus preparations (Figure 2-8A and C). Hence this fragment is a bona fide 
cleavage intermediate that is not induced by the mutations at the N-terminus of 
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integrase. Collectively these results indicate that protease cleavage site 
preference is not affected by the mutations at the integrase N-terminal residue. 
However, in the presence of a fully active protease, the absolute levels of 
integrase decreased (compare total signal between WT and mutant virions at 0 
µM ritonavir) suggesting that the loss of integrase in the mutants requires HIV-1 
protease activity.  
 
The N-terminal mutants of HIV-1 but not MLV impact infection. 
Next, we tested the infectivity of these mutants in human cells. As shown in 
Figure 2-8A, infectivity was 10-20 fold lower for both HIV-1 integrase mutants 
compared to wild-type virus. In contrast, MLV integrase mutants exhibited slight 
decreases in infectivity compared to WT virus in Jurkat cells (Figure 2-8B). 
Notably the levels of integrase in the met or trp mutants vary (Figures 2-6, 2-7 
and data not shown) but the levels of infection are equally refractory indicating 
that the defect is due to a function of the N-terminal amino acid in the 
RT/uncoating process rather than a defect in proteolytic processing. 
 
Although the main catalytic function of retroviral integrase is to integrate viral 
double stranded DNA into the host cell chromosome, numerous studies have 
demonstrated the impact of mutations in the integrase protein on various viral 
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processes including uncoating (214), nuclear import (215, 216) and reverse 
transcription (215, 217-221). In order to determine which step(s) of the viral life 
cycle is affected by the HIV-1 integrase N-terminal mutants, we measured 
relative viral DNA accumulation at different time points following infection of the 
Jurkat cells using quantitative PCR analysis. As shown in Figure 2-8C, both 
methionine and tryptophan mutants of HIV-1 integrase showed substantially 
lower first jump products compared to WT integrase. Approximately 10-20 fold 
decrease was observed at 6 and 18 hours post infection. These results indicate 
that the severe inhibition of HIV-1 infection caused by the substitution of the N-
terminal residue of viral integrase is the result of a block at the reverse 
transcription or uncoating step of the viral life cycle. 
 
N-end Rule Pathway doesn’t target integrase during retroviral life cycle.  
The finding that both stabilizing and destabilizing N-terminal mutants of HIV-1 
exhibited similarly decreased infectivity levels supports our hypothesis that 
integrase is not affected by the N-end rule pathway during viral life cycle. We 
further tested this hypothesis in experiments using viral mutants and cellular 
mutants in the N-end rule. If integrase is affected by the N-end rule pathway, the 
stabilizing N-terminal mutant (methionine) would show similar infectivity on 
different N-recognin deficient MEFs, while our destabilizing mutant (Tryptophan) 
would behave like the WT virus. In contrast to these expectations, our mutants 
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showed the same pattern in their infectivity of N-recognin deficient MEFs (Figure 
2-9). All HIV-1 mutants showed a 5-6 fold decrease in infectivity when all three 
ubiquitin ligases are depleted compared to UBR1-/- UBR2-/- cells. In contrast WT 
MLV and MLV integrase mutants were only slightly decreased and this could be 
attributed to the overexpression of shRNA since the control luciferase knockdown 
also resulted in a decrease in infection (Figure 2-10). 
 
Discussion 
In this study we set out to investigate the role of the N-end rule ubiquitin protease 
degradation pathway in the retroviral life cycle. This pathway has the potential to 
act on viral proteins that are generated from polyproteins by protease cleavage. 
The resultant N-terminal amino acid can vary from the canonical methionine of 
most proteins and the mature protein can be subject to rapid degradation 
according to the N-end rule (197). In looking at HIV-1 by sequence comparison,  
we identified 7 mature proteins that are predicted to have a short half-life 
according to the N-end rule (Table 2-1). Comparing 1850 sequences at the Los 
Alamos HIV Sequence Database that includes all subtypes of HIV-1 and SIVcpz 
showed an absolute conservation for the N-terminal residue of the mature 
proteolytically cleaved form of 4 proteins (p1, TFP, RNaseH and Integrase). 
Figure 2-1 illustrates this for the integrase sequence. Since N terminal amino 
acid residue for these 4 proteins is under selective pressure to be conserved, we 
reasoned the residue at this site might interact with cellular pathways / proteins. 
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We initially used cells lines that were genetically inactivated for the E3 ligases 
involved in the N-end rule recognition N-recognins UBR1, UBR2 and UBR4 
(203). From the reported overlap and redundancy in function we utilized cell lines 
that were multiply inactivated for combinations of the N-recognins. We show that 
while HIV-1 infection is impacted when all three recognins are inactivated, MLV 
infection is only marginally affected. This result implied that an N-end rule target 
protein in the host cell is involved in HIV-1 infection and its stabilization results in 
a reduction of infection. We also conclude that this protein interacts with HIV-1 
but not with MLV and the interaction is not conserved between retroviruses. An 
alternative hypothesis was that the N-end rule pathway interacts with a protein or 
proteins from HIV-1 but not MLV. Regardless of the mode of action, we 
determined that the block to infection is at reverse transcription or uncoating. 
 
In order to determine the potential viral target of the N-end rule pathway we 
decided to examine the role of HIV-1 proteins. We initially focused this study on 
the integrase molecule because it has previously been shown to be a target for 
the N-end rule (203, 205, 206) and it has been a focus for the development of 
small molecule inhibitors in recent years. Previous data had demonstrated that 
ectopically expressed integrase with a destabilizing residue was unstable and 
this instability can be rescued in N-recognin mutants (203). These studies were 
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extended by using ubiquitin integrase fusions that replaced the N – terminus of 
integrase with various amino acids and these experiments validated the action of 
the N-end rule again on ectopically expressed forms of integrase (203). However 
these studies did not determine if the integrase was a target for the N-end rule 
during infection since the question remained whether the N-terminus of integrase 
was open to interaction with N-recognins in the context of the reverse 
transcription complex or the pre-integration complex. These are large molecular 
assemblies in which integrase plays a role. One report did study the N-terminal 
phenylalanine of integrase in the context of viral infection by mutating the 
phenylalanine to the stabilizing methionine residue (206). In this study the 
authors also mutated the C- terminus of reverse transcriptase to compensate for 
any defect in proteolytic processing due to the N-terminal substitution. These 
authors reported that infection was greatly reduced in the methionine (and 
compensation) mutant and they speculate that this may be due to the stability of 
integrase by extrapolating the data from the previous reports (203, 205). In this 
study, we included an additional control by mutating the destabilizing WT 
residue, phenylalanine to another destabilizing and structurally conservative 
aromatic amino acid tryptophan. We found no absolute defect in proteolytic 
processing by the single amino acid mutation as reported previously (206). We 
found that infection was decreased for both mutations compared to the WT virus 
(Figure 2-8A). This result suggests that the severe inhibition of infectivity caused 
by the amino acid substitution at the N-terminal residue of HIV-1 integrase is not 
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related to the N-end rule pathway. It further confirms that the identity of the N-
terminal amino acid of integrase for HIV-1 is vital to its function and explains the 
tremendous selection pressure that results in this phenylalanine residue being 
absolutely conserved. This function is unique for HIV-1 since mutating the N-
terminal residues of MLV had little impact on infection of MLV. 
 
We further observed that mutating the N-terminal amino acid in integrase 
resulted in intravirion instability of the integrase molecule (Figure 2-6). Intravirion 
instability of the members of the Pol polyprotein has been observed in previous 
studies (222, 223). We confirm that this instability is in part due to the action of 
HIV-1 protease since the stability of mutant proteins is restored by inhibiting the 
protease (Figure 2-7). This result suggests that HIV-1 protease may degrade the 
mutant proteins in the virion or that it initiates a cleavage that is acted upon by 
other proteases packaged into virion particles. 
 
Since the N-terminal mutant integrase in the virion still enabled low levels of 
infectivity, we tested the mutant HIV-1 virions in N-recognin deficient cells. We 
found that all mutants had a decreased titer on the triply deficient cells compared 
to the UBR1 -/- UBR2 -/- cells (Figure 2-9).This reduction was not observed for 
MLV and mutants at the N-terminus of its integrase (Figure 2-10). These results 
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support our conclusion that HIV-1 integrase in the context of infection is not a 
target for the N-end rule pathway. 
 
Our results also point to the importance of the first amino acid phenylalanine of 
HIV-1 integrase in its function. This residue is often changed using recombinant 
DNA techniques used to manipulate the integrase coding sequence. Typically 
this involves adding a methionine start codon to the protein to enable expression 
of the integrase molecule (224). Moreover in structural studies residual epitope 
tags are left as N-terminal extensions after protein purification (225). Hence 
future studies should aim to retain the N-terminal phenylalanine especially if 
integrase is studied in a complex with other proteins. Since in vitro assays for 
integrase function are efficient with recombinant N-terminal methionine bearing 
molecules, and we have eliminated interaction of the N-terminus with the N-end 
rule machinery, we speculate that an N-terminal interaction with cellular or viral 
components involving the phenylalanine is crucial for the early pre-integration 
phase of HIV-1 infection. Considering the absolute conservation of this residue, 
this interaction may be a potent target for small molecules to disrupt the viral life 
cycle. 
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Conclusions 
We conclude that HIV-1 integrase is not a direct target for the N-end rule 
pathway mediated degradation during infection. Further, the nature of the N-
terminal residue of integrase is vital for the infectivity of HIV-1, but not MLV. 
 
Materials and Methods 
Reagents, Plasmids and Mutagenesis 
WT, UBR4RNAi, UBR1-/-, UBR2-/- and UBR1-/- UBR2-/-, UBR1-/- UBR2-/-
UBR4RNAi and UBR1-/- UBR2-/-LuciRNAi cell lines were previously established 
(203, 226, 227). 293T and Jurkat cells were obtained from American Type 
Culture Collection (ATCC). The following reagents were obtained through the 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH; 
p24 Monoclonal Antibody (183-H12-5C) from Dr. Bruce Chesebro and Kathy 
Wehrly, HIV-1 HXB2 Integrase Antiserum (aa 23-34)from Dr. Duane P. 
Grandgenett, HIV-1 RT Monoclonal Antibody (MAb21) from Dr. Stephen Hughes, 
Ritonavir. The anti-p30 to MLV was collected from a hybridoma cell line obtained 
from the ATCC (CRL-1912). Secondary p24 antibody for ELISA was collected 
from a hybridoma cell line obtained from ATCC (HB-9725). Antibody isolation 
from the hybridoma cell lines were performed using standard protocols (228). 
MLV integrase rabbit polyclonal antibody was a kind gift from Dr. Monica Roth. 
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Goat-anti-mouse-horseradish peroxidase and goat-anti-rabbit-horseradish 
peroxidase (HRP) secondary antibodies and West Femto enhanced 
chemiluminescent (ECL) HRP substrate were obtained from Thermo Scientific 
(Rockford, IL). Secondary antibody for ELISA; goat-anti-mouse-HRP IgG2A was 
obtained from Southern Biotech (Birmingham, AL) 
 
Following plasmids were used in this study: CSII-EGFP; an HIV-1 based vector 
encoding for GFP driven by EF-1a promoter (229). CSII-DSRed; an HIV-1 based 
vector encoding for Ds-Red. CSII-CMVGFP; an HIV-1 based vector encoding for 
GFP driven by CMV promoter.∆NRF (230); encodes for gag, pol, rev, tat and vpu 
of HIV-1. pMDG (231); encodes for vesicular stomatitis virus glycoprotein. 
pCLMFG-GFP (232); and MLV based vector encoding for GFP, pCMVgp (232); 
encodes for gag and pol of MLV. 
 
Mutations at the N terminal of HIV-1 and MLV integrase were introduced to 
∆NRF and pCMVgp respectively using QuickChange site-directed mutagenesis 
kit (Stratagene, La Jolla, CA). 
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Virus Production, Infections and Culture Conditions 
HIV-1 and MLV vectors were generated by transient transfection of three 
plasmids into 293T cells as described previously (231, 232). For HIV-1 vectors 
15μg of CSII EGFP, 10μg of ∆NRF and 5μg of pMDG were transfected using the 
method of Chen and Okoyama (233). 72 hours after transfection virus was 
collected and filtered through a 0.45 μM membrane. Following normalization via 
p24 ELISA, filtered virus was concentrated by ultracentrifugation (100,000 x g, 2 
hours at 4˚C). Viral pellet was resuspended in Phosphate buffer saline (PBS) and 
aliquots were stored at -80˚C. Viral titers were determined by infecting 1 × 105 
Jurkat cells with 10 fold dilutions of the viral preparation. 72 hours after the 
infection EGFP expression was quantified by flow cytometry on a Becton-
Dickinson FACScalibur. Same procedure was followed for production of MLV 
vectors using following plasmids;15μg of pCLMFG-GFP, 10μg of pCMVgp and 
5μg of pMDG. 
 
MEFs and 293T cells were maintained in Dulbecco’s Modified Eagle Medium 
(Cellgro) supplemented with 10% Fetal Bovine Serum, FBS (Gemini 
Bioproducts). Jurkat cells were maintained in Iscove's Modified Dulbecco's 
Medium (ATCC) supplemented with 20% FBS. 
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Reverse transcription products qPCR assay 
1 × 105 cells were plated into 6 well dishes and infected at an MOI of 1. To 
control for DNA contamination, the virus was treated with 50 units/mL Benzonase 
(Sigma) for 1 hour at 37˚C before it was added to the cells. Infe ctions were 
synchronized by incubating the cells 30 minutes at 4˚C before and after the 
addition of the virus. Controls consisted of uninfected cells or cells infected with 
heat inactivated virus for 36 hours. Cells were harvested and washed with PBS 
at different time points. Cell lysates were prepared by resuspending the cell pellet 
in lysis buffer (Tris pH 8.0, 25 mM EDTA pH 8.0, 100 mM NaCl, 1% Triton X-100, 
and 2 mg/ml proteinase K) and incubating at 55°C overnight. Samples were then 
incubated at 95°C for 15 minutes to inactivate proteinase K. Lysates were used 
directly for qPCR analysis. Following primers were used for qPCR(234): U31 and 
U32 for first jump products, MHC535 and MHC536 for 2LTR circles: 5' β-actin-
ATC ATG TTT GAG ACC TTC AA, 3' β-actin-AGA TGG GCA CAG TGT GGG T, 
U31 - GGA TCT ACC ACA CAC AAG GC, U32 – GGG TGT AAC AAG CTG 
GTG TTC, MH535 – AAC TAG GGA ACC CAC TGC TTA AG, MH536 – TCC 
ACA GAT CAA GGA TAT CTT GTC. QPCR reactions using SYBR green were 
performed using Eppendorf real plex master cycler ep and BioRad SYBR 
SuperMix following the manufacturers protocol. Cycling conditions used were 
95°C for 2 min, followed by 40 cycles of 95°C 30s, 58°C 30s, and 72°C 30s, and 
a final extension of 5 minutes at 72°C for all PCR products. Cycle threshold value 
was used to normalize the DNA amounts to the first time point of the control 
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sample. The melt curve as well as analysis of the PCR products by agarose gel 
electrophoresis confirmed the presence of one product at the expected size (data 
not shown). DNA input was controlled by qPCR amplification of a fragment of the 
β-actin gene.  
 
Enzyme-linked immunosorbent assay (ELISA) 
A 96 well plate (NuncMaxisorp, Fisher Scientific) was coated with a primary p24 
antibody (183-H12-5C) in coating buffer (100 mM Sodium Bicarbonate, pH 8.5) 
and incubated overnight. Wells were then washed 3 times with Phosphate Buffer 
Saline-Tween (PBS-T) and blocked for 1 hour using 5% milk in PBS-T at room 
temperature. Following a 3x wash with PBS-T, viral samples were added to the 
wells at different concentrations in Sodium Chloride-Tris-EDTA (STE) buffer-
empigen (0.1 M NaCl, 10mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 0.1% 
empigen) in triplicates and incubated at 37˚C for 1 hour. Wells were then washed 
3x with PBS-T and secondaryp24 antibody (31-90-25) was added to each well 
and incubated at room temperature for 1 hour. Following a 3x wash with PBS-T 
goat-anti-mouse IgG2A-HRP was added to the wells and incubated for 30 
minutes at room temperature. Wells were then washed 3x with PBS-T and 
3,3’,5,5’-Tetramethylbenzidine, TMB (Sigma) was added to the wells. Following a 
10 minute incubation at room temperature, the reaction was stopped with 2N 
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H2SO4. Absorbance was determined at 450 nm using a microplate reader 
(BioTEK, SynergyMX). 
 
 
Immunoblotting for viral proteins 
Filtered virus containing supernatants were concentrated as described above. 
Following normalization for p24 via ELISA, viral pellets were solubilized in 
loading buffer (0.25M Tris-HCl, pH 6.8, 15% SDS, 50% glycerol, 25% β-
mercaptoethanol, 0.01% bromophenol blue) and proteins were separated by 
SDS-PAGE on a 12% polyacrylamide gel and subjected to immunoblotting using 
the antibodies indicated. 
 
Analysis of intravirion proteolytic processing of HIV-1 polyproteins 
293T cells (1 × 106) were transfected using the method of Chen and 
Okoyama(233) with 15μg of CSII EGFP, 5μg of pMDG, and 10μg of ∆NRF which 
contains different mutations corresponding to the relevant integrase N-terminal 
mutant.8 hours later transfection medium was replaced with culture medium 
containing different concentrations of the HIV-1 protease inhibitor, ritonavir. 48 
hours later virus was collected, filtered and centrifuged at 100,000xg for 2 hours 
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at 4˚C. Purified virions were quantified by p24 ELISA and protein composition of 
the virions was assessed by immunoblotting as described above. 
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Figure 2-1. N terminal residue of HIV integrase is highly conserved. Analysis 
of sequence of the protease cleavage site between RT and integrase of 1850 
isolates of HIV-1 and SIVcpz present in Los Alamos HIV Database 
(http://www.hiv.lanl.gov) using the web alignment tool. Corresponding amino acid 
for the conserved sequence is shown at the bottom. The sequence logo at the 
top was generated using WebLogo (http://weblogo.berkeley.edu/). Arrows 
indicate the protease cleavage site. 
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Figure 2-2. HIV-1 infectivity is decreased when all three N-recognins are 
depleted. WT and N-recognin deficient MEFs were infected with VSVG 
pseudotyped HIV-1-EGFP at an increasing MOI of 0.1, 0.5 and 1. The percent of 
GFP positive cells were determined by fluorescence cytometry 3 days post 
infection. 
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Figure 2-3. Kinetics and nuclear localization of proviral DNA in N-recognin 
deficient cells.UBR1-/- UBR2-/-LuciRNAi(control) and UBR1-/- UBR2-/-
UBR4RNAi cells were infected with VSVG pseudotyped HIV-1-EGFP at an MOI 
of 1. Viral cDNA products were quantified by qPCR at indicated times. (A) First 
jump products. The data are expressed as relative to the control 4hr time point. 
(B) 2LTR circles. The data are expressed as relative to the control 24hr time 
point. The data for the UBR1-/- UBR2-/-UBR4RNAi are the average of UBR1-/- 
UBR2-/-UBR4KD1  and UBR1-/- UBR2-/-UBR4KD2 cells. 
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Figure 2-4. Only some retroviral integrases bear a N-terminal type-2 
destabilizing residue. A comparison of the identity and nature of the amino acid 
at the N-terminus of mature integrase for various retroviruses.  Representatives 
of the family of retroviruses were chosen based on sequence characterization of 
the cleavage site or the integrase protein from the literature (207, 211, 212, 235-
242) 
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Figure 2-5. MLV infectivity is not affected in N-recognin deficient cell. WT 
and N-recognin deficient MEFs were infected with VSVG pseudotyped MLV-
EGFP at an increasing MOI of 0.25, 0.5 and 2.5. The percent of GFP positive 
cells were determined by fluorescence cytometry 3 days post infection. 
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Figure 2-6. Intravirion integrase levels are decreased in HIV-1 integrase N-
terminal mutants. HIV-1 or MLV virions were produced in 293T cells using 
helper plasmids with either WT or engineered mutations for the N-terminus of 
mature integrase. Virions particles were concentrated and capsid equivalent (p24 
for HIV-1 and p30 for MLV) extracts were analyzed by immunoblot analysis. A) 
HIV-1 vector particle extracts probed with p24, integrase or RT antibodies. The 
MLV (ctrl) particle extract serves as a negative control. B) MLV vector particle 
extracts probed with p30 or MLV integrase antibodies. The HIV (ctrl) extract 
serves as a negative control. 
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Figure 2-7. Intravirion processing of Gag and Gag-Pol polyproteins in HIV-1 
integrase N-terminal mutants. WT and mutant HIV-1 virion particles were 
produced in the presence of varying concentrations of the HIV-1 protease 
inhibitor ritonavir and the cleavage pattern of the Gag and GagPol polypeptides 
were analyzed by immunoblot analysis. WT, methionine substituted (Met) and 
tryptophan substituted (Trp) integrase mutants were probed with antibodies to 
integrase (top) or p24 (bottom). 
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Figure 2-8. Effect of N-terminal Integrase mutations on HIV-1 and MLV viral 
infectivity. WT or mutant integrase HIV-1 (A) or MLV (B) viral vectors 
equilibrated to p24 (HIV-1) or p30 (MLV) amounts were incubated with Jurkat 
cells and infectivity was measured by flow cytometry 3 days after infection. MOI 
for WT was measured as indicated in the Methods section and the viral amounts 
corresponding to equivalent p24 or p30 levels were used for integrase mutants 
(C) HIV-1 vectors at an MOI of 1 were incubated with Jurkat cells and viral cDNA 
first jump products were quantified by qPCR at indicated times. The data are 
expressed as relative to the control (wild-type) 2hr time point.  
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Figure 2-9. HIV-1 Integrase N-terminal mutants behave similarly in N-
recognin deficient cells. WT and integrase mutant (Trp and Met) HIV-1 vectors 
were used to infect N-recognin deficient cells. The infectivity was measured by 
flow cytometry 3 days post infection and is expressed relative to infection of the 
UBR1-/- UBR2-/- cell line.  
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Figure 2-10. MLV Integrase N-terminal mutants behave similarly in N-
recognin deficient cells. WT and integrase mutant (Leu and Met) MLV vectors 
were used to infect N-recognin deficient cells. The infectivity was measured by 
flow cytometry 3 days post infection and is expressed relative to infection of the 
UBR1-/- UBR2-/- cell line.  
77 
 
HIV-1 Cleavage 
Site and 
conservation 
Amino Acid at the N 
terminus 
N-end Rule Designation 
MA/CA 
Conserved 
Proline Stabilizing 
CA/p2 
Conserved 
Alanine Stabilizing 
P2/NC 
Variable 
Methionine Stabilizing 
NC/p1 
Conserved 
Phenylalanine Primary Destabilizing 
p1/p6(gag) 
Variable 
Leucine Primary Destabilizing 
NC/TFP 
Conserved  
Phenylalanine Primary Destabilizing 
TFP/p6(pol) 
Variable 
Leucine Primary Destabilizing 
p6(pol)/PR 
Variable 
Proline Stabilizing 
PR/RT 
Conserved 
Proline Stabilizing 
RT/RH(p15) 
Conserved 
Tyrosine Primary Destabilizing 
RH(p15)/INT 
Conserved 
Phenylalanine Primary Destabilizing 
Nef 
Variable 
Leucine Primary Destabilizing 
 
Table 2-1. HIV-1 proteins have N-terminal destabilizing residues 
Comparison of 84 protease cleavage site sequences (27 C-type, 30 B-type and 
27 M-type)(208). The position and the conservation relatives to the most 
common recent common ancestor (MRCA) are shown. The proteins that are 
conserved for a destabilizing residue as confirmed by an analysis of 1850 
isolates of HIV-1 and SIVcpz present in Los Alamos HIV Database 
(http://www.hiv.lanl.gov) are highlighted in bold. 
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Table 2-2. N-terminal integrase mutants of HIV-1. 
 
 
 
 
 
 
 
 
 
Cleavage site (RH/INT) N-end Rule Designation Amino acid at P1’ 
RKVL/FLD (WT) Destabilizing Phenylalanine 
RKVL/MLD Stabilizing Methionine 
RKVL/WLD Destabilizing Tryptophan 
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Table 2-3. N-terminal integrase mutants of MLV. 
 
 
 
 
 
 
 
Cleavage site 
(RH/INT) 
N-end Rule Designation Amino acid at P1’ 
STLL/IEN (WT) Destabilizing Isoleucine 
STLL/MEN  Stabilizing Methionine 
STLL/LEN  Destabilizing Leucine 
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Chapter 3 
 
Nature of the N-terminal Amino Acid 
Residue of HIV-1 RNase H is Critical 
for the Stability of Reverse 
Transcriptase in Viral Particles 
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Summary 
Reverse transcriptase (RT) of Human Immunodeficiency Virus type 1 (HIV-1) is 
synthesized and packaged into the virion as a part of the GagPol polyprotein. 
Mature RT is released by the action of viral protease. However unlike other viral 
proteins RT is subject to an internal cleavage event leading to the formation of 
two subunits in the virion – a p66 subunit and a p51 subunit that lacks the RNase 
H domain. We have previously identified RNase H as an HIV-1 protein that has 
the potential to be a substrate for the N-end rule pathway which is a ubiquitin 
dependent proteolytic system in which the identity of the N-terminal amino acid 
determines the half life of a protein. Here we examined the importance of the N-
terminal amino acid residue of RNase H in the early life cycle of HIV-1. We show 
that changing this residue to a structurally different amino acid than the 
conserved residue leads to degradation of RT and in some cases integrase in the 
virus particle and this abolishes infectivity. Using intravirion complementation 
assays with Vpr fusion proteins we show that liberation of RNase H mutant RT 
from GagPol is necessary for this degradation. Our data also suggests that 
association of RT subunits is impaired in at least one of the RNase H N-terminal 
mutants. These results indicate the importance of the N-terminal amino acid 
residue of RNase H in HIV-1 viral fitness. 
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Introduction 
Like all retroviruses Human Immunodeficiency Virus Type (HIV-1), the causative 
agent of AIDS, synthesizes and packages its main structural and enzymatic 
proteins as precursor polyproteins. For HIV-1 these polyproteins are p55 (Gag) 
and p160 (GagPol). Gag is the most abundant polyprotein and is translated from 
a genomic length mRNA that contains the Gag and GagPol open reading frames. 
The synthesis of GagPol requires a ribosomal frameshift leading to a 
Gag:GagPol ratio of about 20:1 in the virus particle (18). Individual mature viral 
proteins are generated following viral assembly as a result of a series of 
proteolytic cleavage events at specific positions catalyzed by the viral protease 
which is synthesized as a part of GagPol (48).  
 
One protein that is released as a result of proteolytic processing of GagPol is 
reverse transcriptase (RT). RT catalyzes the reaction for the conversion of viral 
RNA to double stranded DNA (243). In contrast to the other viral enzymes 
encoded by the pol gene, RT functions as a heterodimer of two subunits, p66 
and p51 (244-246). Formation of this heterodimer requires the proteolytic 
cleavage of the RNase H domain from one of the p66 subunits resulting in p51 
that is associated with the p66 to form the heterodimer (244). RNA dependent 
DNA polymerase, and RNase H activities of HIV-1 RT are mainly carried out by 
the p66 subunit, while p51 was thought to be enzymatically inactive and only 
serving a structural role (245, 247-250). However, recent structural and 
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biochemical evidence suggests that C-terminal end of the p51 subunit is involved 
in hydrolysis and positioning of the RNA/DNA hybrid formed during the reverse 
transcription process (251-253). 
 
Retroviral RNase H is a member of a family of enzymes that are found in all 
domains of life (254). It functions as an endonuclease which degrades RNA from 
the RNA/DNA hybrid formed during the first phase of reverse transcription. This 
function is crucial for the processing and completion of reverse transcription, as it 
creates an RNA primer for plus strand DNA synthesis and as it facilitates the first 
and second jump by removing the 5' end of viral RNA and tRNA respectively 
(248, 255, 256). In the virus particle RNase H is found both as a part of p66 and 
as a free protein (244). However it is not definitively established whether the 
RNase H species that is cleaved off by the viral protease to create the RT 
heterodimer has any specific function. 
 
The N-end rule pathway is an ubiquitin dependent proteolytic system in which the 
identity of the N-terminal amino acid determines the half life of a protein. Since 
proteolytic cleavage of viral polyproteins can result in N-terminal residues that 
determine a short half life for the cleaved protein according to this rule we have 
recently examined the involvement of the N-end rule pathway in the retroviral life 
cycle. Using N-end rule mutant cells and N-terminal amino acid substitution 
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mutants we studied the effects on the mature integrase protein that bears a 
highly conserved N-terminal destabilizing residue (257). Our results showed an 
impact of the N-end rule pathway on the HIV-1 but not MLV life cycle. However 
the interaction was not at the level of the integrase N-terminal residue (257). One 
of the differences in the protein composition of HIV-1 and MLV is that unlike the 
heterodimeric RT of HIV-1, MLV RT functions as a monomer of about 75kDa 
protein, hence doesn't require a proteolytic cleavage to remove the RNase H 
domain (258, 259). Due to this difference between HIV-1 and MLV and the fact 
that HIV-1 RNase H also has the potential to be a substrate for the N-end rule 
pathway, we turned our attention to this protein.   
 
In this study we investigated the role of the N-terminal amino acid residue of HIV-
1 RNase H. Here we show that the N-terminal residue of RNase H is highly 
conserved and changing this residue to an amino acid that is structurally different 
than the WT residue leads to degradation of RT and in some cases integrase in 
the virus particle. Notably this degradation in the virus particle is independent of 
the N-end rule that would manifest in the target cell. We demonstrate that this 
degradation is processive and does not extend to RT species that are added in 
trans into the viral particle. Our results also indicate that liberation of RT from 
GagPol or a Vpr fusion protein is required for the degradation of RNase H N-
terminal mutants. Moreover we show that N-terminal RNase H mutant RT is not 
degraded in vitro in the presence of excess viral protease. We also present 
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evidence that at least one of the RNase H N-terminal mutants have a defect in 
association of RT subunits. 
Results 
N-terminal amino acid residue of HIV-1 RNase H is highly conserved 
In our previous study we have reported on 7 HIV-1 mature proteins as having 
primary destabilizing residues as defined by the N-end rule (257). Further 
analysis indicated that only 4 of these proteins (p1, Trans frame octapeptide, 
RNase H and Integrase) have a conserved residue at the N-terminus. Here we 
investigate the role of the N-terminal residue of RNase H during HIV-1 infection. 
Comparison of the sequence of the cleavage site between the p51 subunit of RT 
and RNase H in HIV-1 isolates present in Los Alamos HIV sequence database 
reveals that the sequence for the N-terminal amino acid residue of RNase H is 
absolutely conserved for all the isolates found in this database (Figure 3-1). This 
suggests a hypothesis that changing this residue would have deleterious effects 
on viral infectivity. 
 
RNase H N-terminal mutations impact intravirion protein levels and viral 
infectivity 
To test the role of the N-terminal residue of RNase H in the viral life cycle of HIV-
1, we changed this residue to several different amino acids. Selection of mutants 
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was based on N-end rule designation or structure of the specific amino acid as 
compared to the wild type (WT) residue of Tyrosine (Table 3-1). We first 
analyzed the effect of these N-terminal RNase H mutations on viral protein 
packaging and maturation by immunobloting. We observed that viral pellets of 
most of the RNase H mutants contained drastically reduced levels of RT as 
compared to WT viral pellets (Figure 3-2). Extended exposure of the immunoblot 
(using enhanced chemiluminescence for detection) revealed that some mutant 
(i.e. Proline (Pro) and Lysine (Lys)) virions contained barely detectable levels of 
RT, while others contained diminished amounts of p51 (data not shown). In 
contrast, two of the mutants (Tryptophan (Trp) and Phenylalanine (Phe) 
containing structurally similar amino acids to the WT tyrosine residue had slightly 
reduced levels of RT compared to WT (Figure 3-2, top blot). Since we didn't 
observe any low molecular weight peptide fragments using a monoclonal RT 
antibody (Figure 3-2), we also tested some of our mutants with a polyclonal RT 
antibody to detect possible degradation products (data not shown). While this 
analysis revealed the appearance of a predominant immunoreactive peptide of 
between 40 and 30 kDa as well as some minor low molecular level bands in 
three of the mutants (Methionine (Met), Trp and Phe), these peptide fragments 
are not apparent in mutant virions that have drastically decreased levels of RT 
(data not shown). We didn't observe any significant difference between RNase H 
mutants and WT in Gag or GagPol protein production in virus producing cells that 
can explain the lack of intravirion RT (data not shown). We further probed our 
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RNase H mutants for the presence of other HIV-1 proteins, and this analysis 
revealed that some of the mutants also had diminished levels of intravirion 
integrase (Figure 3-2, middle panel). The mutants that had the most effect on the 
RT levels (i.e. Pro and Lys) showed the most pronounced decrease in virion 
integrase levels as well. We further probed the RNase H mutant virions for viral 
capsid protein (p24) to determine whether the mutations we introduced caused 
any gross aberrations in assembly or processing. As shown in the bottom panel 
of Figure 3-2, a product of the Gag processing, p24, is found in all mutants 
suggesting WT levels of protease activity on the Gag polyproteinin the virions.  
Next, we tested the infectivity of the N-terminal RNase H mutants of HIV-1. As 
shown in Figure 3-3, infectivity was slightly decreased (by a factor of 0.75) for Trp 
and Phe mutants that were not compromised for RT levels in the virions. 
Infectivity was undetectable in all the other mutants tested except for the Met 
mutant which had about 100 fold decrease in infectivity compared to WT.  
 
Packaging and processing of viral polyproteins with RNase H N-terminal 
mutations 
Despite the correct processing of Gag to p24 in all of the N-terminal RNase H 
mutants tested (Figure 3-2 bottom blot), diminished levels of RT and integrase in 
some mutants indicate the possibility of aberrant packaging or aberrant 
processing of GagPol. To better assess this, we analyzed the presence of 
88 
 
GagPol, Gag and other proteolytic processing products in the mutant virions. We 
produced WT and RNase H mutant virions (Met and Leu which are typical for 
residual RT of other mutants) in the presence of varying amounts of ritonavir, an 
HIV-1 protease inhibitor. Following concentration, virions were analyzed by 
immunoblotting. As shown in Figure 3-4 bottom panel, WT and mutant virions 
showed similar patterns of cleavage intermediates when probed for p24. As the 
concentration of ritonavir increased the levels of processed p24 decreased with a 
corresponding increase in the amounts of higher molecular weight products such 
as Gag and GagPol (Figure 3-4, bottom panel). Notably at the highest 
concentration of ritonavir the Gag and GagPol levels were similar in all virions 
suggesting that the mutants do not compromise assembly of these into virion 
particles. When probed with RT antibody, cleavage patterns of WT and mutant 
virions are only comparable at the higher ritonavir concentrations (Figure 3-4, top 
blots). For virions produced in the presence of 1 or 0.5 µM of ritonavir, WT virus 
shows the predicted processing intermediates consistent with previous reports 
(212, 213). There is a loss of immunoreactive epitopes in the two mutants 
examined (Figure 3-4 top panel). From this analysis we cannot conclude whether 
a higher molecular weight intermediate or the RT p66 species is mainly 
susceptible to the degradation observed in the mutants. However the 
appearance of similar levels of GagPol and Gag in both mutants and WT at the 
highest ritonavir level indicates correct packaging of these polyproteins in RNase 
H N-terminal mutants. 
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Delivery of RT independent of GagPol into HIV-1 virions 
Our analysis of proteolytic processing in RNase H mutants did not allow us to 
conclude whether this degradation requires only the RT p66 species or a higher 
molecular processing intermediate. In addition we wondered if this degradation 
can affect WT RT p66 species that may dimerize with a mutant RT if both were 
present in the virion. To test these questions we delivered p66 synthesized 
independent of GagPol into virions containing WT or RNase H mutant GagPol. 
This was accomplished by using fusions to the HIV-1 accessory protein vpr that 
is packaged into the virion by binding to the p6 domain of Gag (260). We 
generated constructs by fusing vpr to WT or RNase H mutant RT-Integrase 
(Figure 3-5A and B). The protease cleavage site (PC) between protease and RT 
to the end of the vpr was retained to enable cleavage and release of RT-
Integrase in the virus particle. We generated WT or N-terminal RNase H mutant 
viral particles in the presence or absence of vpr fusion constructs. Concentrated 
virions were analyzed by immunoblotting following p24 ELISA to enable 
equivalent loading based on viral capsid concentration. As shown in Figure 3-6 
top panel, when probed with a vpr antibody, WT or mutant viruses complemented 
with vpr-RT-INwt fusion constructs contain the predicted 4 bands as a result of 
protease cleavage at 3 different sites; between vpr and RT, p51 and RNase H 
and RNase H and integrase (Figure 3-6 top panel: lanes marked +vpr-RT-INwt). 
When we probed vpr-RT-IN complemented mutant virions with an RT antibody 
we observed the almost complete rescue of both RT subunits only when the vpr 
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constructs contained WT or Trp mutant RNase H fusions (Figure 3-6A and C 
middle panel). RNase H N-terminal mutants that are structurally different than the 
WT showed either diminished levels of RT subunits (Figure 3-6C) or the 
appearance of only low levels of p51 (Figure 3-6A). Notably the vpr fusions 
appear to be at similar levels in virion particles (Figure 3-6 top panel and middle 
panel) and the RT subunits are subject to degradation suggesting that these are 
the substrates for proteolysis. Similar to the results obtained with the vpr-RT-
Integrase fusions, we observed the appearance of both RT subunits only in the 
virions complemented with vpr-RTwt or vpr-RTtrp when we delivered vpr-RT 
fused RNase H mutants (data not shown). These results support the idea that the 
mutant RT p66 is the substrate for proteolysis once it is liberated from the 
polyprotein (GagPol or from the vpr fusion). 
 
Infectivity of Vpr-RT-Integrase complemented viruses 
Since the vpr-RT-IN complemented RNase H N-terminal mutants showed rescue 
of intravirion RT when complemented with WT or Trp mutants, we tested if this 
molecular rescue also extends to infectivity of the RNase H mutants. We infected 
Jurkat cells with WT or mutant vpr-RT-IN complemented viruses (Figure 3-7). As 
predicted by immunoblotting results, infectivity of Leu, Met and Pro mutants were 
rescued to similar levels by complementation with vpr-RT-INwt (Figure 3-7B, C 
and D). We also observed rescue of infectivity by vpr-RT-INtrp, albeit at different 
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levels for each mutant (Figure 3-7B, C and D). In contrast, complementation with 
vpr-RT-IN constructs containing RNase H mutants that had diminished levels of 
RT in the virion did not rescue infectivity in any of our mutants (Figure 3-7B, C 
and D). Of note there is a general slight decrease in infectivity in WT virions that 
are complemented with different vpr constructs.  
 
 
RNase H N-terminal mutant RT is stable in vitro 
Our observations show that RT of most of the N-terminal mutants of RNase H 
are degraded in virions and that this degradation is dependent on release of the 
mutant p66 from the polypeptide in which it is embedded (Figure 3-4 for GagPol, 
Figure 3-6 for vpr-RT-Integrase). However, it is not clear whether this 
degradation is caused by the viral protease (for example by the mutation 
uncovering cryptic target sites) or a cellular protease that is packaged into the 
virion. We first investigated this by using a rabbit reticulocyte lysate (RRL) in vitro 
transcription/translation system. Since Gag is the dominant protein species 
translated from full length viral mRNA this would interfere with our ability to detect 
RT that is made from the frameshifted GagPol polyprotein (18). Hence we used a 
GagPol transcript with an engineered frameshift that would produce only full 
length GagPol polyprotein (Figure 3-5C). We further introduced an N-terminal 
RNase H mutation (Pro) to this construct since it is the mutant with the most 
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drastic effect on RT stability in the virion. Previous studies on in vitro translated 
GagPol polyprotein showed that the encoded protease cannot completely 
process the GagPol precursor to mature viral proteins (213, 261, 262). A strong 
initial cleavage event between p2 and nucleocapsid (NC) was observed followed 
by minor cleavages at other sites (213). However, addition of HIV-1 protease to 
the reaction has been shown to generate mature viral proteins (261). In our 
assay system we first translated the GagPol in vitro and then incubated the final 
product with the exogenous HIV-1 protease and used immunoblot analysis to 
probe for RT release and stability. As shown in Figure 3-8A, in the absence of 
exogenous protease we observe the predicted proteins that result from a single 
dominant cleavage of GagPol by the intrinsic protease (40 kDa, and an 
approximately 120 kDa). We also observed lower molecular weight peptides 
using this RT monoclonal antibody, consistent with several minor cleavage 
products observed previously (213, 262). Consistent with previous findings, 
addition of HIV-1 protease resulted in the processing of GagPol with the 
appearance of p24 for both WT and the RNase H proline mutant, when probed 
with a p24 antibody (Figure 3-8A, top blot). We also observed the appearance of 
the p51 and p66 subunits of RT from WT GagPol following incubation with the 
viral protease (Figure 3-8A, bottom blot). In contrast to the intravirion degradation 
of RT in the RNase H proline mutant, the in vitro maturation of GagPol containing 
the RNase H proline mutant resulted in stable RT subunits (p51 and p66) at 
similar levels to WT levels (Figure 3-8A, bottom blot). Addition of greater 
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concentrations of viral protease or longer incubations times did not reveal any 
additional cleavages of the final products (data not shown). 
 
RNase H N-terminal Proline mutant causes impairment in dimerization of 
RT subunits 
The above in vitro experiments suggest that viral protease may not be 
responsible for the degradation of intravirion RT of some RNase H N-terminal 
mutants, there remains the possibilities that the contents of the viral milieu, 
concentration of viral protease or specific interactions between the viral proteins 
inside the virion are required for the mutant RT to be degraded in the virus 
particle. To properly investigate these possibilities we packaged the p66 RT 
subunit into virions without the need to fuse it to any protein. This would enable a 
test of intravirion stability of RT in the absence of an active viral protease. To this 
end we utilized a previously described construct pLR2P-vpr-p51-IRES-p66 (vpr-
p51/p66) (263). In this construct, vpr fused p51 subunit is packaged into the 
virion through the interaction of vpr with the p6 domain of Gag, while the p66 
subunit is packaged via its interaction with the p51 subunit in the vpr-p51 fusion 
(263). Since the vpr-p51/p66 construct makes it difficult to distinguish between 
vpr-p51 fusion protein and p66 on immunoblots probed with an RT antibody 
(264), we generated a construct that contains 50 amino acids from the C 
terminus of HIV-1 protease between the vpr and p51 (Figure 3-5D). This enabled 
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us to distinguish between vpr-pro50-p51 and p66 on immunoblots. To test for the 
involvement of viral protease in the degradation of RT in RNase H mutants, we 
inactivated the viral protease by introducing a D25A mutation into the protease 
gene in our viral production helper plasmid ΔNRF. Using these constructs we 
produced WT or RNase H mutant vpr-pro50-p51-IRES-p66 complemented 
virions, and analyzed them by immunoblotting. As shown in Figure 3-8B, both 
WT and Trp mutant complemented protease inactive virions contain the expected 
peptides for vpr-pro50-p51 and p66 when probed with an RT antibody. In 
contrast, RNase H Pro mutant complemented virions lack the peptide for the p66 
subunit and only contain the vpr-pro50-p51 peptide (Figure 3-8B, top blot). 
Because p66 is translated and packaged to the virion as a separate (non fusion) 
protein in the vpr-p51/p66 construct we wanted to determine whether it is stably 
expressed in the cells used to produce the virus. To this end we analyzed 
extracts of 293T cells co-transfected with WT or RNase H mutant vpr-pro50-p51-
IRES-p66 constructs and ΔNRF D25A. As shown in Figure 3-8C, both vpr-pro50-
p51 fusion protein and p66 are expressed from WT and RNase H mutant (Trp 
and Pro) containing constructs. Of note we observe two bands related to p66 in 
our mutants when expressed in 293T cells (Figure 3-8C). Similar p66-related 
peptides were previously detected by others when mutations introduced into RT 
were close to the dimer interface and were thought to be generated by the action 
cellular proteases (265, 266). Even though these results indicate that RNase H 
proline mutant p66 is expressed in the virus producing cells, there still remains 
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the possibility that it is not packaged into the virions due to a defect in binding to 
vpr-pro50-p51 caused by the mutation. To test this possibility we performed a co-
IP assay. For this we incubated extracts of 293T cells co-transfected with ΔNRF 
D25A and vpr-pro50-p51Δp66, vpr-pro50-p51/p66wt or vpr-p51/p66pro with a vpr 
antibody. Bound protein complexes were pulled down with Protein G conjugated 
beads and analyzed by immunoblotting. As shown in Figure 3-8D top panel, both 
vpr-pro50-p51 and p66 can be detected in both the lysate (Inp) and 
immunoprecipitate (IP) from the cells expressing WT p66 (lanes under pLR2P 
WT). In contrast, p66 is only present in the lysate and not in the 
immunoprecipitate of the cells expressing RNase H proline mutant p66 (Figure 3-
8D top panel, lanes under pLR2P Pro). These results indicate that dimerization of 
RT p66 with p51 is impaired when the N-terminal residue of RNase H is changed 
to Proline. 
 
Discussion 
RNase H of HIV-1 is cleaved out of about half of the viral p66 RT species that are 
synthesized and this results in the association of heterodimeric subunits of RT, 
p51 and p66 (244). This proteolytic cleavage releases RNase H into the virion 
environment and this mature form of RNase H bears a conserved N-terminal 
amino acid residue that makes it a potential substrate for the cellular N-end rule 
pathway (Figure 3-1). In this study we set out to examine the role of the N-
terminal residue of RNase H on the life cycle of HIV-1. To this end we generated 
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virions containing mutations of the N-terminal RNase H tyrosine residue. We 
observed that most of the amino acid substitutions led to a complete or almost 
complete absence of RT in the virion (Figure 3-2). The nature of the amino acid 
substitution that leads to the absence of detectable RT in the virion was 
important since mutants that contained structurally similar amino acids to WT (i.e. 
Trp and Phe) at the N-terminus of RNase H had both subunits of RT at levels 
similar to WT. Similar observations were reported by another group following 
introduction of multiple mutations in the p51/RNase H cleavage site region (222). 
Since that study introduced multiple mutations that led to the degradation of RT 
in the virus particle, it was not possible to determine which mutation is 
responsible or what type of amino acids are tolerated at any specific residue. In 
this study we report on mutagenesis of only the N-terminal residue and our 
results point to the importance of the nature of the amino acid at the N-terminal 
amino acid residue of the RNase H for the stability of RT in the virus particle. 
This is also strongly suggested by the high conservation of the Tyr residue 
across HIV-1 isolates (Figure 3-1). 
 
In addition to the absence of RT, some RNase H mutants also contained 
diminished amounts of intravirion integrase (Figure 3-2). There is also a 
concomitant appearance of  peptide around 25 kDa (Figure 3-2 and data not 
shown). It is probable that a selection of RT mutations lead to a structural change 
in the RT-Integrase polyprotein that leads to the exposure an alternative protease 
97 
 
cleavage site in integrase. It is important to note that some of the mutant virions 
didn't contain significant amounts of this possible alternative cleavage product 
including the proline mutant that has the most drastic effect on RT stability. This 
may indicate a different or additional mechanism for integrase degradation for 
these mutants. It is important to note that relative amounts of integrase correlated 
with the relative amounts of RT found in the RNase H mutants. This may indicate 
the degradation of a higher molecular weight intermediate induced by the 
structural change in the polyprotein. 
The fact that we observed proteolytic processing of Gag to p24 by viral protease 
and the presence of at least some amounts of integrase in each mutant 
combined with the observation that GagPol and Gag is found to be expressed in 
the RNase H mutants  indicate that any presumed deficiency in GagPol 
production and packaging cannot explain the drastically low levels of RT found in 
some of the RNase H N-terminal mutants. 
Infectivity of the N-terminal RNase H mutants correlated with RT content in the 
virion. With viruses containing structurally similar amino acids to WT Tyr amino 
acid at the RNase H N-terminus (Trp and Phe) reporting only a slight decrease in 
infectivity while the other mutants resulted in complete or almost complete lack of 
infectivity (Figure 3-3). Even though some mutants retained a limited amount of 
p51 in the virus particle the presence of p66 is required for the reverse 
transcription process (248). One of our mutants (Met) showed limited levels of 
infectivity. A closer look at the immunoblots probed with monoclonal or polyclonal 
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RT antibody reveals that the Met mutant did contain limited amounts of p66 in the 
virion that explains the residual level of infectivity observed in this mutant (data 
not shown). 
 
Despite the degradation of both RT and integrase, we didn't observe a deficiency 
in intravirion incorporation of GagPol in our RNase H mutants. Moreover 
appearance of identical proteolytic cleavage patterns in Gag processing indicates 
that activity of viral protease is not impacted by mutations at the N-terminal 
amino acid residue of HIV-1 RNase H (Figure 3-4).  
 
The mechanism of the formation of the RT p51/p66 heterodimer is not clearly 
established. Two possible models have been proposed. In the concerted model, 
p66 and p51 subunits are separately cleaved out of different GagPol molecules 
and come together to form the heterodimer. In contrast, the sequential model 
posits that following the formation of an initial homodimer by two p66 subunits the 
RNase H domain of one of the subunits is cleaved to form the heterodimer of 
p66/p51. Even though most of the crystallographic and functional evidence points 
to the sequential model, definitive evidence is still missing. Since the RT of some 
our RNase H N-terminal mutants are degraded in the virus particle, we explored 
the possibility of this degradation affecting a non-mutant RT p66 species by 
delivering the RT as a GagPol independent vpr fusion protein into the virus. 
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While these results do not clearly distinguish between the two models of RT 
heterodimer formation, they indicate that degradation of RT caused by the 
RNase H N-terminal substitutions is confined to the specific p66 species that 
contains the mutation. Hence we observed that trans-complementation with WT 
RT-Integrase vpr fusion protein substantially rescued infectivity in our RNase H 
mutants.  
 
Proteolytic processing of the precursor polyproteins of HIV-1 is an ordered series 
of events carried out by the viral protease following the assembly of viral 
components. A conformational change due to a mutation in the polyprotein may 
expose alternative cleavage sites leading to additional cleavages of the viral 
polyprotein and result in loss of infectivity. We tested the possibility that the 
RNase H N-terminal mutants were degraded by the HIV-1 protease using both 
an in vitro and an intravirion assay. In vitro experiments relied on the ability of 
externally added viral protease to complete the processing of in vitro translated 
GagPol precursor leading to the appearance of mature viral proteins (261). With 
the caveat that in vitro conditions may not exactly represent the conditions inside 
the virus particle we did not observe any degradation of RT for the proline RNase 
H mutant (Figure 3-8A). This led us to question the role of HIV-1 protease in the 
degradation of RT in N-terminal RNase H mutants. An intravirion assay showed 
the absence of RT p66 species bearing the proline RNase H mutant containing in 
the virions with the inactivated viral protease (Figure 3-8B) although its 
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expression in the producer cell was unaffected. However further analysis using 
co-IP showed that the absence of RT p66 in these virions is caused by the 
impaired interaction between vpr-pro50-p51 and RNase H proline mutant p66 
(Figure 3-8D). This indicates that dimerization of RT subunits is impaired in this 
RNase H mutant. Previous studies have shown that dimerization of RT subunits 
is a prerequisite for the activity of the enzyme (267-269). Moreover, mutations in 
the tryptophan repeat motif of RT has been shown to cause defects in 
dimerization (268, 269) and these results were later confirmed using the same 
pLR2p constructs utilized in this study (266). While some of these tryptophan 
motif mutants also showed decreased levels of RT in the virus particle (268), this 
degradation is not as drastic as the degradation we observed in RNase H N-
terminal mutants. It is possible that the lack of dimerization is a side effect of the 
structural change brought upon by this mutation, and not the cause of the 
degradation in the virus particle. Others have speculated that RT-RNase H 
cleavage site is not involved in the RT dimer formation (270). Here we show 
evidence that at least one of the amino acids in this cleavage site has a role in 
association of RT subunits. 
 
It is notable that while the results from our in vitro assay indicates that viral 
protease may not be responsible for the degradation of RNase H proline mutant 
of RT p66, our vpr complementation and protease inhibitor experiments clearly 
indicate that release of the mutant RT p66 species from the polyproteins by viral 
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protease cleavage is required, since GagPol and vpr fused polyproteins were 
stable even when harboring the unstable RNase H mutations. 
 
Recent advances in proteomic technology have enabled more detailed analysis 
of the protein content of HIV-1 virus particles. Indeed multiple studies to date 
have identified cellular proteins packaged into HIV-1 virions (271-274). Relevant 
to this study the presence of multiple cellular proteases have been reported. 
However there is no significant overlap in the identity of the proteases identified 
in these studies. Indeed the only protease that is common to two of these studies 
is carboxypeptidase D (271, 272). In addition, Santos et al. found this protease 
only in viral particles generated from one of the cell lines they used (272). While 
this indicates the importance of the specific cell line and methodology used for 
these studies, we believe that RT degradation of mutants is caused by a 
protease that is broadly expressed since the same phenomenon (of degradation 
of RT mutants as result of mutations in this region) was observed when monkey 
kidney cells (COS-7) and human T cells (MT-2) were used for virus production 
(222). 
 
Due to its importance as an anti-viral target reverse transcriptase of HIV-1 is one 
of the most highly studied proteins. Several groups have introduced amino acid 
substitutions at different subdomains of RT(222, 223, 251, 268, 275-278). Many 
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of these mutants led to destabilization of the RT protein in the virus particle as 
well as loss of infectivity. Some studies have concluded that the viral protease is 
responsible for the degradation of the mutant RT. Nature and the position of the 
mutation may determine which protease is responsible for RT degradation. 
However it is important that the potential effect of cellular proteases should not 
be ignored based on the lack of degradation of GagPol polyprotein in the 
absence of active viral protease. Our results indicate that liberation of the mutant 
subunit from the fusion polypeptide is a prerequisite for degradation and previous 
results should be re-evaluated in this light. This study could have implications for 
the development of small molecules that distort the structure of the HIV-1 
polyprotein in the Pol polypeptide to engage a protease for the destruction of 
essential viral enzymes. 
 
Materials and Methods 
Reagents and Cell Culture 
293T and Jurkat cells were obtained from the American Type Culture Collection 
(ATCC). 293T cells were maintained in Dulbecco’s Modified Eagle Medium 
(Cellgro) supplemented with 10% Fetal Bovine Serum, FBS (Gemini 
Bioproducts). Jurkat cells were maintained in Iscove's Modified Dulbecco's 
Medium (ATCC) supplemented with 20% FBS. 
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The following reagents were obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH; p24 Monoclonal Antibody (183-
H12-5C) from Dr. Bruce Chesebro and Kathy Wehrly, HIV-1 HXB2 Integrase 
Antiserum (aa 23-34)from Dr. Duane P. Grandgenett, HIV-1 RT polyclonal 
antibody, pEGFP-Vpr (cat# 11386) from Dr. Warner C. Greene and Ritonavir.  
Monoclonal antibody for RT (1.149 B6) was previously isolated and 
characterized(279). 
Mouse monoclonal (IgG2a) antibody against HIV-1 vpr was obtained Cosmo Bio 
USA (Carlsbad, CA). 
Secondary p24 antibody for ELISA was collected from a hybridoma cell line 
obtained from ATCC (HB-9725). Antibody isolation from the hybridoma cell line 
was performed using standard protocols as described previously (257). 
Secondary antibody for ELISA; goat-anti-mouse-HRP IgG2A was obtained from 
Southern Biotech (Birmingham, AL). Goat-anti-mouse-horseradish peroxidase 
and goat-anti-rabbit-horseradish peroxidase (HRP) secondary antibodies and 
West Femto enhanced chemiluminescent (ECL) HRP substrate were obtained 
from Thermo Scientific (Rockford, IL).  
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Plasmid Constructs and Mutagenesis 
Plasmids were used for VSVg pseudotyped HIV-1 production were: CSII-EGFP; 
an HIV-1 based vector encoding for GFP driven by EF-1a promoter. ∆NRF; 
encodes for gag, pol, rev, tat and vpu of HIV-1. pMDg; encodes for vesicular 
stomatitis virus glycoprotein.  
 
RNase H N-terminal mutations were introduced into ∆NRF by PCR mutagenesis 
(PCR Primers available upon request). PCR products which contain the specific 
mutations were cut with KpnI and ligated back into KpnI digested ∆NRF plasmid.  
 
Viral protease inactivating D25A mutation was introduced into ∆NRF by overlap 
PCR (Primers available upon request). Final PCR product was cut with SacII and 
SbfI, and cloned into ∆NRF. 
 
For the vpr complementation assays, a mammalian expression plasmid, pRK5, 
was used to clone the vpr fusion proteins. Vpr was amplified from pEGFP-Vpr 
using following primers; forward; 5' 
CTCGGATTCACCGCCATGGAACAAGCCCCAGAAGAC 3', reverse; 5' CGC 
GAA GCT TCA GTT CCA GAT CTG AGT AGG ATC TAC TGG CTC CAT TTC 
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TT 3'. PCR products were digested with BamHI and HindIII and cloned into 
pRK5. This construct, pRK5-vpr, was used for cloning WT or RNase H mutant 
RT or RT-Integrase. pRK5-vpr-RT constructs were generated by amplifying RT 
sequence including the protease cleavage site between Protease and RT from 
WT or RNase H mutant ∆NRF constructs using following primers; Forward 5' 
GCT CAA GCT TAC TTT AAA TTT TCC CAT TAG TCC 3', Reverse 5' GCT CAA 
GCT TTT ATA GTA CTT TCC TGA TTC 3'. PCR products were then digested 
with HindIII and cloned into pRK5-vpr. Same strategy was used for generating 
pRK5-vpr-RT-IN constructs, the following reverse primer together with forward 
primer above was used for generating the PCR product including RT and 
Integrase; 5' GCT CAA GCT TTT AAT CCT CAT CCT GTC TAC 3'.  
 
pLR2P-vpr-p51-IRES-p66 was previously described and was a kind gift from Dr 
John Kappes (263). RNase H mutants were cloned into this plasmid by first 
amplifying the ΔNRF construct with the corresponding mutation with the following 
primers; 5' CAG TAA ATT TAA AGC CCG GGA TGG ATG G 3' and 5' GGA TCT 
CGA GTT ATA GTA CTT TCC TGA T 3'. PCR products were digested with XmaI 
and XhoI and cloned into pLR2P-vpr-p51-IRES-p66. pLR2P-vpr-pro50-p51-
IRES-p66 was generated by first amplifying a region of ΔNRF containing 150 
nucleotides of viral protease and p51 subunit of RT using the following primers; 5' 
TAG ATC AGA TCT AAT TGG AGG TTT TAT CAA AGT AG 3' and 5' ATC TAC 
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ACG CGT TTA GAA AGT TTC TGC TCC TAT 3'. PCR products were digested 
with BglII and MluI and ligated into pLR2P-vpr-p51-IRES-p66 cut with the same 
enzymes. pLR2P-vpr-p51Δp66 was generated by first digesting pLR2P-vpr-p51-
IRES-p66 with XmaI and XhoI and then re-ligating the plasmid after filling the 5' 
overhangs generated by the restriction enzymes with T4 DNA polymerase. 
 
pRK5-GagPol was generated by first PCR amplifying GagPol from ΔNRF using 
the following primers; 5' TCG ATT GAA TTC GCC ATG GGT GCG AGA GCG 
TCG G 3' and 5' GCT CCT GTC GAC TTA ATC CTC ATC CTG TCT 3'. PCR 
products were digested with EcoRI and SalI and cloned into pRK5. pRK5-
GagPol-FS was generated by overlap PCR using following primers: Left pair 5' 
GGC AAA GAA GGG CAC ACA GCC 3' and 5' CCC TGA GGA AGT TAG CCT 
GTC TCT CAG TAC 3', right pair 5' GGC TAA CTT CCT CAG GGA AGA TCT 
GGC CTT CC 3' and 5' GTT GAC AGG TGT AGG TCC TAC 3'. Final product 
was digested with ApaI and BclI and cloned into pRK5-GagPol. RNase H 
mutants were cloned into pRK5-GagPol-FS from the ΔNRF containing the 
corresponding mutation using BsrGI digestion. 
. 
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Virus production and infectivity assays 
HIV-1 vectors were generated by transiently transfecting three plasmids into 
293T cells as described previously (231, 232). 15μg of CSII EGFP, 10μg of 
∆NRF and 5μg of pMDG were transfected using the method of Chen and 
Okoyama(233). For vpr complementation assays 10 µg of the corresponding vpr 
fusion protein expressing plasmids were used for transfections. 72 hours after 
transfection virus was collected and filtered through a 0.45 μM membrane. 
Filtered virus was concentrated by ultracentrifugation (100,000 x g, 2 hours at 
4˚C). Viral pellet was resuspended in Phosphate buffer saline (PBS) and aliquots 
were stored at -80˚C. Concentrated virions were normalized to WT virus using 
p24 ELISA as described previously (257). MOI for WT was determined by 
infecting 1 × 105 Jurkat cells with 10 fold dilutions of the viral preparation. 
Infections for mutant or vpr complemented viruses were done by using p24 
equivalent levels of concentrated viral supernatants (based on p24 ELISA) that 
correspond to the MOI value for WT virus. 72 hours after the infections EGFP 
expression was quantified by flow cytometry on a Becton-Dickinson FACScalibur. 
 
In vitro transcription and translation assays 
Transcription and translation of WT and RNase H mutant pRK5-GagPol-FS was 
performed using the TNT coupled Reticulocyte Lysate System with SP6 
polymerase (Promega) according to the manufacturer's instructions. 4 µL of the 
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translation product was used for western blotting. For the external HIV-1 
protease processing reactions 4 µL of translation products were incubated with 1 
µg of HIV-1 protease (Abcam) in phosphate buffer (25 mM NaCl, 25 mM 
Na2HPO4, 1 mM dithiothreitol and pH 7.0) in 20 µL reaction volumes at 30°C for 
2 hours. The entire reaction volume was used for western blotting.  
 
Analysis of viral proteins by immunoblotting 
Viral pellets and in vitro transcription/translation products were dissolved in 
loading buffer (0.25M Tris-HCl, pH 6.8, 15% SDS, 50% glycerol, 25% β-
mercaptoethanol, 0.01% bromophenol blue) and proteins were separated by 
SDS-PAGE on a 12% polyacrylamide gel and subjected to immunoblotting using 
the antibodies indicated.  
For the analysis of protein expression from vpr-pro50-p51-IRES-p66, 5 x 105 
293T cells which were cotransfected with this plasmid together with ΔNRF D25A 
were lysed in cell lysis buffer (20 mM Tris-HCl [pH 8.0], 1 mM CaCl2, 150 mM 
NaCl, 1% Triton) and proteins were separated by SDS-PAGE on a 12% 
polyacrylamide gel and analyzed by immunoblotting as described above. 
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Co-Immunoprecipitation (Co-IP) Assay 
293T cells were co-transfected with ΔNRF D25A and pLR2P-vpr-p51-IRES-
p66wt, pLR2P-vpr-p51-IRES-p66pro or pLR2P-vpr-p51Δp66 as described above. 
24 hours after transfection 5 x 106 cells were lysed in immunoprecipitation buffer 
(20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton and 0.5% sodium 
deoxycholate). 5% of this lysate was used as input for the assay. Rest of the 
lysate was incubated with the Vpr antibody for 1 hour at 4˚C. This mixture was 
then incubated with protein G beads (bio-world) for 2 hours at 4˚C. Lysate -bead 
mixture was washed with the immunoprecipitation buffer 3 times and 
immunoprecipitated proteins were eluted with loading buffer (0.25M Tris-HCl, pH 
6.8, 15% SDS, 50% glycerol, 25% β-mercaptoethanol, 0.01% bromophenol 
blue). This eluate was used for SDS-PAGE and immunoblotting as described 
above. 
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Figure 3-1. N terminal residue of HIV-1 RNase H is highly conserved. 
Sequence of the protease cleavage site between RT (p51) and RNase H was 
analyzed for1850 isolates of HIV-1 and SIVcpz present in Los Alamos HIV 
Database (http://www.hiv.lanl.govwebcite)using the web alignment tool. Amino 
acid that corresponds to the conserved sequence is shown at the bottom. The 
sequence logo at the top was generated using WebLogo 
(http://weblogo.berkeley.edu/webcite).  
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Figure 3-2. Changing the N terminal residue of HIV-1 RNase H leads to 
instability of RT and integrase in the virus particle. Equivalent p24 amounts 
of WT and RNase H N terminal mutant virions were analyzed by western blotting 
following production in 293T cells using helper plasmids and concentration by 
ultracentrifugation. Particles were probed with RT(top), integrase(middle) and 
p24(bottom) antibodies 
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Figure 3-3. Effect of N-terminal RNase H mutations on HIV-1 infectivity. 
Jurkat cells were infected with p24 equivalent amounts of VSVg pseudotyped WT 
or mutant RNase H mutant HIV-1 vectors. Infectivity was measured by flow 
cytometry 3 days post infection. MOI for WT was measured as indicated in the 
Methods section. 
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Figure 3-4. Intravirion processing of Gag and Gag-Pol polyproteins in HIV-1 
RNase H N-terminal mutants. WT and two representatives of RNase H mutant 
HIV-1 virion particles were produced in the presence of varying concentrations of 
the HIV-1 protease inhibitor ritonavir and the cleavage pattern of the Gag and 
Gag Pol polypeptides were analyzed by immunoblot analysis. WT, as well as 
methionine (Met) and Leucine (Leu) RNase H mutants were probed with 
antibodies to RT (top) or p24 (bottom).  
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Figure 3-5. Constructs used for Vpr complementation and in-vitro studies. 
Position and identity of RNase H N-terminal substitutions are indicated. 
Frameshift causing mutation for pRK5-GagPol-FS is shown. PC: protease 
cleavage site between viral protease and RT. 
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Figure 3-6. Analysis of Vpr-RT-Integrase complemented HIV-1 virions. HIV-1 
virions with GagPol containing WT (B) and RNase H N-terminal mutants Leu(A) 
or Pro (C) were produced in 293T cells with helper plasmids in the presence or 
absence of expression plasmids encoding for Vpr-RT-Integrase fusion proteins 
with WT or N-terminal RNase H mutant RT. Concentrated virions were 
normalized for p24 with ELISA and analyzed by western blotting using vpr (top), 
RT(middle), p24(bottom) antibodies.  
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Figure 3-7. Infectivity of Vpr-RT-Integrase complemented WT or RNase H N-
terminal mutant viruses. Jurkat cells were infected with p24 equivalent WT (A) 
or N-terminal RNase H Leu (B), Met (C), Pro (D), Trp (E) mutant VSVg 
pseudotyped HIV-EGFP containing WT or RNase H mutant vpr-RT-IN fusion 
proteins. Infectivity was determined by flow cytometry 3 days post infection. MOI 
for WT was measured as described in Methods.  
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Figure 3-8. In vitro and intravirion analysis of the role of viral protease in 
the degradation of RNase H mutants. A. pRK5-GagPol-FS was used for in 
vitro transcription translation by RRL.  Translation products were incubated at 
30˚C for 2h with HIV-1 protease or phosphate buffer and analyzed via 
immunoblotting. B. Protease inactivating D25A mutant virions were produced in 
293T cells in the presence of vpr-pro50-p51/p66 plasmids encoding WT or 
RNase H mutant p66. Concentrated virions were analyzed by western blotting 
using the indicated antibodies following normalization via p24 ELISA. C. 293T 
cells were co-transfected with vpr-pro-p51/p66 plasmids encoding WT or RNase 
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H mutant p66 and ΔNRF D25A. Cellular extracts were analyzed by 
immunoblotting. D. 293T cells were co-transfected with vpr-pro-p51/p66 plasmids 
encoding WT or RNase H mutant p66 and ΔNRF D25A. Co-IP was performed on 
cell extracts using vpr antibody and protein G beads. Arrows indicate the identity 
of the RT, p24 and vpr antibody detected fragments. Antibodies used for each 
blot is indicated in bold with an α sign.  
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Table 3-1. HIV-1 RNase H N-terminal mutants 
Cleavage site 
(RT/RH) 
N-end Rule 
Designation 
Amino acid at P1’ Reason for 
selection 
 
AETF /YVD (WT) Destabilizing Tyrosine WT 
AETF /MVD Stabilizing Methionine N-end rule 
AETF /FVD Destabilizing Phenylalanine Structurally 
conserved 
AETF /WVD Destabilizing Tryptophan Structurally 
conserved 
AETF /TVD Stabilizing Threonine  N-end rule 
AETF /LVD Destabilizing Leucine N-end rule 
AETF /KVD Destabilizing Lysine Long basic side 
chain 
AETF /AVD Stabilizing Alanine N-end rule 
AETF /PVD Stabilizing Proline Drastic structure 
change 
AETF /GVD Stabilizing Glycine  Small side chain 
AETF /SVD Stabilizing Serine N-end rule 
AETF /VVD  Stabilizing Valine  Small hydrophobic 
side chain 
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Chapter 4 
 
Characterization of Resistance to 
Retroviruses and Retroviral Vectors 
in a Human Myeloid Cell Line 
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Summary 
Retroviruses interact with various supportive and restrictive factors in the host 
cell throughout their replication cycle. Recent years have seen an increase in the 
efforts to identify host cell factors involved in retroviral infection. Cell lines that 
are non-permissive to retroviral infection have been particularly useful in 
discovering major host cell proteins involved in viral life cycle. Here we describe 
characterization of a human myeloid leukemia cell line, KG-1, that is resistant to 
infection by retroviruses and retroviral vectors. We show that KG-1 cells are 
completely resistant to infection by Vesicular Stomatitis Virus Glycoprotein 
(VSVG) pseudotyped retroviruses as well as VSV due to a defect in VSVG 
binding. Moreover our results indicate that entry by xenotropic retroviral envelope 
glycoprotein RD114 is impaired in KG-1 cells. Finally we also discovered a post-
entry block at early phase of the retroviral life cycle in KG-1 cells.  
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Introduction 
As obligate intracellular pathogens retroviruses are intimately dependent on host 
cell factors throughout their life cycle. Since the viral genome only encodes a 
limited number of genes, retroviruses need to utilize various functions of the host 
cell machinery to complete their replication. In addition to the factors that are 
exploited by retroviruses (called cofactors), several cellular proteins have been 
found to act in an inhibitory role against retroviral infection. These are called 
restriction factors. Various methods have been used to identify retroviral 
cofactors and restriction factors including genomewide RNAi screening (49-51), 
analyses of host proteins that interact with specific viral proteins (21, 97) and 
characterization of cells refractory to viral infection (23, 130).  
 
Our laboratory as well as other groups previously isolated mammalian cell lines 
resistant to infection by retroviruses using different methods (229, 280). 
Characterization of some of these cell lines led to identification of multiple host 
factors that are involved in retroviral infection such as Zinc Finger Antiviral 
Protein and fasciculation elongation protein zeta-1 (281, 282). Moreover, one of 
the HIV-1 co-receptors, CXCR4, was identified by cDNA library complementation 
of non-permissive cells (30). Collectively these and similar studies indicate the 
usefulness of non-permissive cells in understanding retrovirus-host interactions.  
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Vesicular Stomatitis Virus (VSV) is an enveloped virus with a negative stranded 
RNA genome and is a member of the family Rhabdoviridae. Despite causing only 
mild disease in humans, VSV has been studied extensively due to its potential as 
an oncolytic agent and the use of its envelope glycoprotein (VSVG) to alter 
tropism of retroviral vectors (283-286). Broad tropism of VSV makes these VSVG 
pseudotyped retroviruses excellent gene delivery tools. This remarkable broad 
tropism of VSV indicates that the receptor for VSVG mediated entry must be 
ubiquitously present in all the widely differing cell types from different species 
that have been transduced. Prompted by this observation, several studies have 
suggested that plasma membrane lipids such as phosphatidyl serine or 
gangliosides can serve as the cellular receptors of VSV (287-289). However, 
subsequently Coil and Miller showed more direct evidence that phosphatidyl 
serine is not the receptor for VSV even though it may be involved in a later step 
following receptor mediated endocytosis (290).  
 
Two recently published studies have increased our understanding of VSVG 
mediated binding to cells. Bloor et. al. have shown that gp96, a ubiquitous 
endoplasmic reticulum chaperone, can rescue VSVG binding deficiency in a 
mouse B cell line that was generated by chemical mutagenesis. Based on this 
observation the authors propose that gp96 is either directly interacting with the 
VSVG receptor or is required for the synthesis of the functional receptor (291). In 
a more recent study, Finkelshtein et al. showed that low density lipoprotein (LDL) 
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receptor functions as the major entry receptor for VSV, while the other members 
of the LDL receptor family are used as the alternate receptors (292).  
 
In this study we investigated the resistance to retrovirus and VSV infection in a 
lymphomyeloid progenitor cell line called KG-1 cells. A study in late 80s have 
demonstrated that these cells are refractory to transduction by a Murine 
Leukemia Virus (MLV) based vector (293). Here we show that KG-1 cells are 
impaired in binding VSV and VSVG pseudotyped retroviruses. Our results also 
indicate that the presence of functional LDL receptor family members is not 
sufficient for VSVG binding. We further demonstrate that retroviruses 
pseudotyped with a xenotropic retroviral envelope glycoprotein, RD114, are 
impaired in their entry to KG-1 cells. Finally our results indicate that post entry 
KG-1 cells are refractory to infections by retroviruses.  
 
Results 
KG-1 cells are resistant to infection by HIV-VSVG and MLV-VSVG  
During gene transfer experiments in our laboratory, we observed differential 
efficiency in infectivity of different cell lines by VSVG pseudotyped HIV-1 (HIV-
VSVG) based vectors. Figure 4-1 illustrates this for GFP encoding HIV-VSVG in 
6 different human cell lines. While some cell lines (such as a T cell line, Cem-A) 
125 
 
showed substantially lower levels of transduction efficiency than others we 
observed no GFP positive cells in the KG-1 population (Figure 4-1). Since non-
permissive cell lines can be powerful tools to understand virus-host interactions 
we decided to characterize the block to HIV-VSVG infection further in KG-1 cells. 
First we infected KG-1 cells with HIV-VSVG at higher multiplicities to test whether 
the block to infection can be overcome which can be indicative of a restriction 
factor that can be saturated. As shown in Figure 4-2A, even at multiplicity of 
infection (MOI) of 10 we didn't observe any transduction in KG-1 cells. To test 
whether this block is unique to HIV-1 we used another retrovirus; Murine 
Leukemia Virus (MLV). Again we observed no infection in KG-1 cells incubated 
with GFP encoding VSVG pseudotyped MLV (MLV-VSVG) at an MOI of 10 
(Figure 4-2A). These results indicate that KG-1 cells are resistant to VSVG 
pseudotyped retrovirus infection. Absolute resistance to retroviruses in KG-1 
cells raised the possibility of a general block to viral infection in KG-1 cells. To 
test this we infected these cells with a virus from a different family. To this end 
we utilized measles virus which is a negative stranded RNA virus of the 
paramyxovirus family. We infected Jurkat and KG-1 cells with measles virus 
encoding a GFP gene and scored GFP positive cells 48 hours after infection. As 
shown in Figure 4-2B, KG-1 were infected with measles virus approximately 50% 
less efficiently than Jurkat cells at an MOI of 3. Therefore the block to retroviral 
infection we observed in KG-1 cells is not caused by a general resistance to virus 
infection. 
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HIV-VSVG infection is impaired at or before reverse transcription in KG-1 
cells 
Next, we determined which stage of the HIV-1 life cycle is impaired in KG-1 cells. 
We first isolated total DNA from Jurkat and KG-1 cells at different time points 
following infection with HIV-VSVG and tracked the presence of reverse 
transcription products via quantitative PCR (qPCR) using different primer sets. 
We also isolated DNA from cells that were cultured for 6 weeks after infection 
with HIV-VSVG and tested the presence of integrated provirus in KG-1 and 
Jurkat cells. As shown in Figure 4-2C we detected no HIV-1 proviral DNA in KG-
1 cells infected with HIV-VSVG. This confirms our initial observation using EGFP 
reporter. Similarly we detected very low levels of 2LTR circles (at least 2 logs 
lower than Jurkat cells) in KG-1 cells as compared to Jurkat cells at 48 hours 
post infection (Figure 4-2D). While 2LTR circles serve as surrogate markers for 
defective integration, substantially lower numbers such as the ones we observe 
in KG-1 cells compared to infectable Jurkat cells indicate a decrease in viral 
cDNA that reaches the nucleus. We also found low levels of early reverse 
transcription (first jump) products 8 hours after infection in KG-1 cells compared 
to Jurkat cells (Figure 4-2E). It is important to note that the levels of first jump 
products detected in KG-1 cells were similar to what was obtained with non-
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infected cells. These results indicate the presence of a major block to HIV-VSVG 
infection at or before reverse transcription followed possibly by another block at a 
later stage. 
 
KG-1 cells cannot be infected by VSV due to a defect in VSVG binding  
Since our qPCR experiments didn't allow us to determine at which point before 
reverse transcription retrovirus infection was blocked in KG-1 cells we decided to 
further characterize viral entry via VSVG in these cells. To test this, we 
determined if infection by VSV is blocked in KG-1 cells. To this end we utilized a 
virus called VSV-eGFP (a replication competent VSV) that contains the VSV 
genome encoding an eGFP coding sequence as an extra gene between G and L 
gene junctions. We infected KG-1 and Jurkat cells with VSV-eGFP at different 
multiplicities and tracked GFP expression using flow cytometry at different time 
points (data not shown). Figure 4-3A shows the result of a VSV-eGFP infection at 
an MOI of 50 with GFP expression measured at 24 hours post infection. We 
observed no GFP expression in KG-1 cells infected with VSV-eGFP (Figure 4-
3A). These results combined with the results obtained using VSVG pseudotyped 
retroviruses indicate that there may be a block to VSVG mediated entry in KG-1 
cells. To test this possibility further, we examined entry of VSVG pseudotyped 
retroviruses to KG-1 cells. KG-1 and Jurkat cells were incubated with HIV-VSVG 
at 4˚C for 1 hour and washed to remove unbound viral particles. Cells were then 
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moved to 37˚C to initiate entry and start the infection. At different time points post 
infection cells were collected, washed and treated with trypsin to remove surface 
bound virions. Cells were then lysed and analyzed by immunoblotting for the 
presence of HIV-1 capsid protein (p24) as an indicator of viral entry. As shown in 
Figure 4-3B, while we detected increasing levels of p24 in Jurkat cells over time, 
we didn't detect any p24 in KG-1 cells. This clearly indicates a defect in entry of 
HIV-VSVG to KG-1 cells. Next we determined whether VSVG binding is affected 
in these cells. Using the same assay as above we infected KG-1 and Jurkat cells 
with HIV-VSVG. However the cells were not treated with trypsin and instead 
washed extensively with cold PBS after collection at different time points post 
infection. We reasoned that any bound virus that had not been internalized would 
still be detected. As shown in Figure 4-3C, presence of p24 is detected in Jurkat 
cells even when cells were kept at 4˚C (0h time point). In contrast we didn't 
detect any p24 in KG-1 cells at any point after infection (Figure 4-3C). These 
results indicate a VSVG binding defect in KG-1 cells. Next we validated this 
result using a different assay. KG-1 and Jurkat cells were incubated with HIV-
VSVG at 4˚ C for 1 hour. Cells were then washed extensively with cold PBS and 
the presence of bound VSVG pseudotyped virus on the cell surface was assayed 
using a primary antibody against VSVG and secondary antibody containing a 
fluorescent tag (Alexa 488). Fluorescence was scored using flow cytometry. As 
shown in Figure 4-3D and E, while bound VSVG is clearly detected in Jurkat cells 
(Figure 4-3E), no shift in fluorescence and hence no bound VSVG is detected in 
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KG-1 cells (Figure 4-3D). All these results collectively indicate that VSVG binding 
is impaired in KG-1 cells. 
 
Functional LDL uptake in KG-1 cells 
While our results so far suggests that KG-1 cells have a defect in VSVG binding, 
another group has previously generated a Murine cell line through chemical 
mutagenesis that was found to be impaired in VSVG binding (291). The results of 
that study suggests that the endoplasmic reticulum chaperone gp96 may be 
required for VSVG binding. To test whether the absence of gp96 can explain the 
VSVG binding defect in KG-1 cells we probed KG-1 and Jurkat cell lysates for 
the presence of gp96 via immunoblotting. We found that gp96 is expressed in 
KG-1 cells at comparable levels to Jurkat cells (Figure 4-4A). Hence gp96 
deficiency doesn't explain the defect on VSVG binding in KG-1 cells.  
The identity of the receptor for VSVG has remained a mystery until recently 
despite the widespread usage of this glycoprotein in gene transfer experiments 
and the broad tropism of VSV. Results of a recent study suggests that LDL 
receptor family acts as the receptor for VSVG mediated entry (292). Since our 
results suggests that KG-1 cells are deficient in VSVG binding, we tested 
whether functional LDL receptor family members are present on KG-1 cells. For 
this we utilized an LDL uptake assay using fluorescently labeled LDL (LDL-DiI) 
(294). To our surprise, KG-1 cells showed robust LDL uptake at levels 
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comparable to control Jurkat cells (Figure 4-4B and C). We observed the same 
result when we performed this assay using different concentrations of DiI-LDL 
and various incubation times (data not shown). This result indicates that KG-1 
cells contain functional LDL receptor family members and that the presence of 
LDL receptor family members is not sufficient for VSVG binding. 
 
 
Entry of RD114 pseudotyped retroviruses is impaired in KG-1 cells 
Our results above did not allow us to conclude whether there is a block to 
retroviral life cycle in KG-1 cells since the resistance we observed for HIV-VSVG 
and MLV-VSVG seems to be caused by a deficiency in VSVG binding (Figure 4-
2). To test whether KG-1 cells are infectable by retroviruses we used a different 
envelope glycoprotein to mediate the entry of our retroviral vectors. To avoid any 
blocks in viral binding we limited our search to envelope proteins with known 
receptors that are expressed in KG-1 cells. RD114, the envelope glycoprotein of 
a feline endogenous retrovirus fit this criteria (295, 296). The receptor for this 
glycoprotein was characterized as a neutral amino acid transporter called 
SLC1A5 (297). A search on the GEO profiles database (298) also revealed that 
this gene is expressed in KG-1 cells (GEO accession GDS2251, (299)) . 
Therefore we produced RD114 pseudotyped GFP encoding HIV-1 and MLV 
vectors and tested the infectivity of these vectors in KG-1 and Jurkat cells. As 
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shown in Figure 4-5A, similar to the VSVG pseudotyped vectors we observed no 
infectivity in KG-1 cells using RD114 pseudotyped HIV-1 and MLV while Jurkat 
cells were infected at high levels with HIV-GFP (85%) and MLV-GFP (55%) at 
the titers used. We performed qPCR assays to pinpoint the position of this block. 
Similar to VSVG pseudotyped vectors we observed background levels of early 
RT (First Jump) products (Figure 4-5B), and the absence of 2LTR circles (Figure 
4-5C) in KG-1 cells infected  with RD114 pseudotyped HIV-GFP. To test whether 
the RD114 pseudotyped HIV-1 can enter KG-1 cells, KG-1 and Jurkat cells were 
incubated with the virus at 4˚C for 1 hour and infection was initiated by moving 
the cells to 37˚C. 2 hours post infection cells were collec ted and either washed 
extensively with PBS or treated with trypsin to remove particles bound outside 
the cell. Cell lysates were analyzed by immunoblotting for the presence of p24. In 
contrast to the results obtained with VSVG pseudotyped virus, we detected the 
presence of virus in the absence of trypsin treatment (Figure 4-5D, KG-1, lane 
labeled no trypsin). However we did not detect any viral capsid protein after 
trypsin treatment (Figure 4-5D, KG-1, lane labeled trypsin). These results 
indicate that RD114 pseudotyped HIV-1 vector can bind but cannot enter KG-1 
cells. 
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KG-1 cells are refractory to retroviruses pseudotyped with amphotropic 
envelope 
Lack of entry observed for the RD114 pseudotyped retroviruses prompted us to 
search for another retroviral envelope glycoprotein with a known receptor. We 
decided to use amphotropic MLV envelopes 4070A and 10A1 which utilize 
sodium phosphate co-transporters Pit1 and Pit2 for entry (300). Moreover 4070A 
enveloped MLV has been previously used to study infectivity of MLV in KG-1 
cells (293). Notably viruses pseudotyped with the amphotropic envelopes had 
very low titers in our hands. While titers were increased after concentration, to 
test infectivity of KG-1 cells at high enough viral titers we decided to utilize 
spinoculation for the infection assays with amphotropic envelopes. As shown in 
Figure 4-6A, KG-1 cells showed low levels of infectivity (between 20-30 fold) 
compared to Jurkat cells after spinoculation with 4070A pseudotyped MLV over a 
range of MOIs. Similar results were obtained after spinoculation with 4070A 
pseudotyped HIV-1, but infectivity difference between Jurkat and KG-1 cells was 
less (6-8 fold) (Figure 4-6B). We obtained similar results using 10A1 envelope 
pseudotyped viruses (data not shown). While the levels of GFP positive cells 
were lower, infectivity difference observed between KG-1 and Jurkat cells were 
comparable when these cells were infected without spinoculation (data not 
shown). Similar results were also observed when a different reporter (Ds-Red) 
and a different promoter driving the reporter expression (CMV) in the vector were 
used (data not shown). To better pinpoint the stage in the HIV-1 life cycle that is 
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impaired in KG-1 cells we performed qPCR experiments as described above. As 
shown in Figure 4-6C, levels of early RT (first jump) products were similar 
between KG-1 and Jurkat cells at 8 hours post infection. This indicates not only 
similar levels of reverse transcription progression but also similar levels of viral 
entry in Jurkat and KG-1 cells. In contrast to the early RT products, we observed 
8-10 fold difference in the amount of 2LTR circles at 48 hours post infection 
between KG-1 and Jurkat cells (Figure 4-6D). While 2LTR circles are considered 
to be dead end products which is the result of the ligation of the linear reverse 
transcription product, they serve as surrogate readout of nuclear import. Hence 
these results indicate a defect in late reverse transcription or nuclear import in 
KG-1 cells. To test whether the difference observed in the number of GFP 
positive cells following 4070A pseudotyped HIV-1 infection in KG-1 and Jurkat 
cells is reflective of the difference in the amount of integrated provirus, we 
cultured these cells for 4 weeks after infection. The continued culture of the cells 
will eliminate un-integrated products by dilution and degradation. As shown in 
Figure 4-6E, there is a 6-8 fold difference in the levels of integrated provirus 
between KG-1 and Jurkat cells. These observations are consistent with the 
results obtained for the functional GFP positive cells assay 3 days post infection 
(Figure 4-6A) and 4 weeks post infection (Figure 4-7A). The difference in the 
number of GFP positive cells between Jurkat and KG-1 cells after infection with 
4070A pseudotyped MLV-GFP is also maintained when the cells were cultured 
long term (Figure 4-7B).  
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Accessory factors encoded by lentiviruses have been shown to be crucial in the 
infection of certain cell types (145, 160). The helper plasmid we use in this study 
does not encode for vpr, nef and vif proteins. To test whether these accessory 
factors can alleviate the block observed in KG-1 cells we utilized a vector that 
contains all the accessory factors. As shown in Figure 4-7C we observed no 
difference in the relative infectivity of KG-1 cells as compared to Jurkat cells 
using this vector when compared to the vector that lacked some of the accessory 
factors (Figure 4-7A). We conclude that the resistance to infection in KG-1 cells 
cannot be alleviated by the presence of HIV- accessory factors.   
 
Discussion 
In this study we characterized the resistance to retroviral and VSV infection in a 
cell line that was previously shown to be partially refractory to MLV based vectors 
(293). Characterization of non-permissive cells - either generated by 
mutagenesis or naturally occurring - to retroviral infection has been a powerful 
tool for discovering host proteins involved in viral life cycle in the past two 
decades including two of the most studied restriction factors, APOBEC3G and 
TRIM5α as well as the HIV-1 co-receptor CXCR4 (23, 30, 130). The non-
permissive cell line we used in this study, KG-1 cells, were isolated from a bone 
marrow aspirate of a patient with acute myelogenous leukemia (301). 
Interestingly KG-1 cells show characteristics of myeloid progenitor cells, and are 
sometimes described as myeloblasts (302, 303). Moreover they express one of 
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the markers of bone marrow derived progenitor cells, CD34 (293). Previous 
studies have shown the differentiation potential of KG-1 cells to mature dendritic 
cells indicating the immature characteristics of these cells (302). These 
properties of KG-1 cells made them a frequent research tool when studying 
myeloid cancers and gene transfer into hematopoietic progenitor cells. Our 
experience with KG-1 cells began when we were studying gene transfer 
efficiency by lentiviral vectors to different hematopoietic cell lines. We observed 
an absolute resistance to both HIV-VSVG and MLV-VSVG even at high 
multiplicities and decided to investigate it further. Analysis of the accumulation of 
viral cDNA products indicated that the block to infection is at the level of early 
reverse transcription or at an earlier step. This result guided us to identify the 
lack of VSVG mediated binding as the reason for the inability of VSVG 
pseudotyped retroviruses and VSV to infect KG-1 cells. Biochemical and 
fluorescence based assays we performed to reach this conclusion relied on the 
binding of the virus particles to the receptors on the cell surface at 4˚ C. It may be 
argued that in KG-1 cells binding of VSVG to its cellular receptor is too weak to 
detect at this temperature. Notably we still didn't detect any virus particles inside 
or bound outside the cells even when the cells were incubated at 37˚C  for KG-1 
cells in contrast to Jurkat cells.   
To our knowledge KG-1 cells represent the first human cell line that is deficient in 
VSVG binding and entry. Previously a mouse B cell line had been characterized 
to be deficient for VSVG binding following mutagenesis with a chemical mutagen, 
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ICR191 (291). The authors of that study identified a frameshift in the gene 
encoding for the heat shock protein gp96. Complementation with a functional 
gene for gp96 restored VSVG mediated binding and entry by retroviral vectors 
(291). As a follow up to this study, the same group demonstrated using plasma 
membrane profiling that cell surface expression of some of the LDL receptor 
family members was decreased in the cells lacking gp96 (304). Notably neither of 
these studies confirmed these results on different cells by depletion of gp96. We 
note an inconsistency in the data of that study since one clone that didn't express 
gp96 showed low level infectivity by VSVG pseudotyped MLV vector (291). Our 
results indicate that KG-1 cells express gp96 and we conclude that this is not the 
mechanism for the VSVG binding defect in KG-1 cells. 
 
Another group published a different study identifying the LDL receptor family 
members as the cellular receptors of VSVG (292). This work relies on the 
observation that soluble LDL receptors can bind VSVG and inhibit plaque 
formation by VSV and exogenous addition of LDL receptor to LDL receptor 
deficient human fibroblasts increased infection by VSVG but not LCMV 
pseudotyped retroviruses. However since LDL receptor deficient cells can still be 
infected by VSV it was hypothesized that other members of the LDL receptor 
family can be utilized by VSVG for binding and entry (292). We tested this in 
VSVG binding deficient KG-1 cells using a fluorescent LDL uptake assay. Our 
results indicate that KG-1 cells are capable of functional LDL uptake. Even 
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though our experimental system doesn't allow us to determine whether LDL 
binding and uptake kinetics is different between KG-1 and Jurkat cells, we can 
conclude that functional LDL receptor family members are present in KG-1 cells. 
This result doesn't necessarily exclude the possibility that LDL receptor family 
members are required for VSVG binding. It is possible that presence LDL 
receptor family members on the cell surface is simply not sufficient for VSVG 
binding and entry. Several viruses require more than one entry factor on the cell 
(28, 29, 305, 306). It is conceivable that VSVG binding requires another protein 
which may be missing or abnormal in KG-1 cells. Another possibility is that KG-1 
cells express a factor that prevents surface expression or modification of the 
VSVG receptor. Our preliminary studies with cell fusion indicates that this block 
to VSVG binding may be dominant (data not shown).  
 
Interestingly the envelope protein we chose (RD114) to test retroviral infectivity in 
KG-1 cells following the observation of VSVG binding defect also failed to 
facilitate viral entry. Receptor for this envelope glycoprotein was discovered via 
cDNA complementation of NIH3T3 cells which do not support infection with 
RD114 unless treated with tunicamycin, which inhibits N-linked glycosylation of 
proteins (297). In our hands, Tunicamycin treatment of KG-1 cells didn't have any 
effect to RD114 mediated retroviral entry (data not shown). Our results suggest 
that RD114 mediated entry but not binding is blocked in KG-1 cells. It has been 
previously shown that RD114 pseudotyped viruses enter the cells via a pH 
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independent path (307). While this suggests that fusion of viral and cellular 
membrane may be happening at the cell surface, there is no detailed study of 
RD114 mediated viral entry. It has recently been shown that cellular entry of HIV-
1 involves receptor mediated endocytosis and the fusion happens at the 
endosomes in some cell types despite the lack of requirement for pH change 
(32). A similar mechanism of entry may be used for RD114 mediated entry. It is 
conceivable that endocytosis through the RD114 receptor is impaired in KG-1 
cells. It is also possible that RD114 entry requires more than one receptor and 
this co-receptor is missing in KG-1 cells. Further experimentation is needed to 
differentiate between these and other possible mechanism of inhibition of RD114 
mediated viral entry in KG-1 cells. 
 
Retroviral infection was previously tested in KG-1 cells by using an MLV based 
vector pseudotyped with amphotropic 4070A envelope glycoprotein (293). In the 
aforementioned study analysis of viral cDNA by southern blotting in the infected 
cells revealed the absence of integrated provirus while the presence of viral 
cDNA was detected using Hirt extraction of low molecular weight DNA molecules 
in the cells. Our results contradict with this observation as we observed 
integrated provirus through GFP expression in KG-1 cells cultured for up to 6 
weeks after transduction with MLV pseudotyped with the same amphotropic 
envelope. We observed similar results with HIV-1 and also observed the 
presence of proviral DNA in KG-1 cells via qPCR analysis. Discrepancy between 
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our results and the previous observation could be caused by the difference in 
sensitivity of the assays. Since even with spinoculation we observed very low 
levels of MLV infectivity in KG-1 cells, it is possible that integrated provirus may 
not be detectable by southern blot at low multiplicities. Moreover our qPCR 
results indicate that HIV-1 infection in KG-1 cells is impaired at the nuclear import 
or late reverse transcription step. This means that reverse transcription products 
are found in substantially higher amounts in KG-1 cells than the integrated 
proviral DNA. If a similar mechanism acts on MLV infection unintegrated viral 
DNA may be detected with better sensitivity than integrated provirus. 
 
There are three major restriction factors identified so far that affect the early 
phase of the HIV-1 life cycle; APOBEC3G, Trim5α and SAMHD1. Viral restriction 
by APOBEC3G requires expression of this protein in producer cells (23). Since 
we produced our viral vectors in 293T cells which don't express APOBEC3G, 
APOBEC3G cannot be the reason for the block to HIV-1 infection in KG-1 cells. 
Trim5α is a pattern recognition receptor that acts on the viral core and prevents 
reverse transcription to proceed (130, 142). Our results show that reverse 
transcription processing is not blocked in KG-1 cells suggesting that abnormally 
acting human Trim5α is not the reason for the inhibition of HIV-1 and MLV in 
these cells. Finally, SAMHD1 is a deoxynucleoside triphosphohydrolase which 
can restrict retroviral infection by depleting the nucleotide pool in non-dividing 
cells (184, 185, 308). While our qPCR results are partially in line with SAMHD1 
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restriction, it is highly unlikely that SAMHD1 can have such a substantial effect 
on infectivity of dividing cells which have high levels of nucleotide pools. 
 
In conclusion, in this study we identify multiple blocks to infection by different 
viruses and viral vectors in KG-1 cells. Our results indicate that KG-1 cells can be 
useful tools to identify another component of VSVG binding as well as the 
mechanism of entry via RD114 glycoprotein. Finally understanding the reason 
behind the block to retroviral infection in KG-1 cells may lead to identification of a 
novel restriction factor. 
 
Materials and Methods 
Reagents and Cell Culture 
293T, Jurkat, KG-1, Cem-A, Molt and Cem-SS cells were obtained from the 
American Type Culture Collection (ATCC). 293T cells were maintained in 
Dulbecco’s Modified Eagle Medium (Cellgro) supplemented with 10% Fetal 
Bovine Serum, FBS (Gemini Bioproducts). Rest of the cells were maintained in 
Iscove's Modified Dulbecco's Medium (ATCC) supplemented with 20% FBS. 
The following reagents were obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH; p24 Monoclonal Antibody (183-
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H12-5C) from Dr. Bruce Chesebro and Kathy Wehrly, pSV-Ψ-MLV-env- from Dr. 
Nathaniel Landau. 
Goat-anti-mouse-horseradish peroxidase and goat-anti-rabbit-horseradish 
peroxidase (HRP) secondary antibodies and West Femto enhanced 
chemiluminescent (ECL) HRP substrate were obtained from Thermo Scientific 
(Rockford, IL).  
Rabbit polyclonal Antibody against gp96 was obtained from GeneTex (Irvine, 
CA). 
Mouse monoclonal antibody against GAPDH was obtained from ABM 
(Richmond, BC, Canada). 
VSVG mouse monoclonal antibody was obtained from KeraFAST. 
DiI-LDL was obtained from Kalen Biochemical (Montgomery Village, MD) 
VSV-eGFP was a kind gift from Dr. Asit Pattnaik. 
Measles-GFP was a kind gift from Stephen Russell. 
 
Plasmid Constructs 
Plasmids used for pseudotyped Retrovirus Production: 
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For HIV-1: CSII-EGFP; an HIV-1 based vector encoding for GFP driven by EF-1a 
promoter. ∆NRF; encodes for gag, pol, rev, tat and vpu of HIV-1. HIG; an NL4-3 
based vector described previously was a gift from Dr. Louis Mansky.  
pRK5-Nef was cloned after PCR mediated amplification of the nef coding 
sequence from HIV-1 NL4-3 (obtained from the NIH AIDS reagent program). It 
was cloned into EcoRI and HindIII sites into the expression vector pRK5 
(Addgene). 
For MLV: pCLMFG-GFP; an MLV based vector encoding GFP driven by CMV 
promoter. pCMVgp; encodes for gag and pol of MLV driven by CMV promoter. 
Vectors used for retroviral pseudotyping: 
pMDg; encodes for vesicular stomatitis virus glycoprotein, 
pHCMV-RD114; encodes for RD114 glycoprotein 
pSV-A-MLV; Encodes for amphotropic (4070A) MLV envelope 
pRK5-10A1; encodes for amphotropic (10A1) MLV envelope 
 
Virus Production and Infectivity Assays 
HIV-1 and MLV vectors were generated by transient transfection of three 
plasmids into 293T cells as described previously (231, 232). For HIV-1 vectors 
15μg of CSII EGFP, 10μg of ΔNRF and 5μg of the relevant envelope 
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glycoprotein encoding plasmid were transfected using the method of Chen and 
Okoyama (233). 72 hours after transfection virus was collected and filtered 
through a 0.45 μM membrane. Filtered virus was concentrated by 
ultracentrifugation (100,000 × g, 2 hours at 4°C). Viral pellet was resuspended in 
Phosphate buffer saline (PBS) and aliquots were stored at −80°C. Viral titers 
were determined by infecting 1 × 105 Jurkat cells with 10 fold dilutions of the viral 
preparation. 72 hours after the infection EGFP expression was quantified by flow 
cytometry on a Becton-Dickinson FACScalibur. Same procedure was followed for 
production of MLV vectors using following plasmids;15μg of pCLMFG-GFP, 10μg 
of pCMVgp and 5μg of the relevant envelope glycoprotein.  
 
Reverse transcription products qPCR assay 
1 × 105 cells were plated into 6 well dishes and infected at an MOI of 1. Cells 
were kept at 4°C for 1 hour before and after the addition of virus to synchronize 
the infections. Controls consisted of uninfected cells or cells infected with heat 
inactivated virus for 36 hours. Cells were harvested and washed with PBS at 
different time points; 8 hours for first jump products, 48 hours for 2LTR circles 
and 6 weeks post infection for full product. Cell lysates were prepared by 
resuspending the cell pellet in lysis buffer (Tris pH 8.0, 25 mM EDTA pH 8.0, 100 
mM NaCl, 1% Triton X-100, and 2 mg/ml proteinase K) and incubating at 55°C 
overnight. Proteinase K was inactivated by treating the lysate at 95˚C for 15 
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minutes. Lysates were used directly for qPCR analysis. Following primers were 
used for qPCR [57]: for first jump products; U31 - GGA TCT ACC ACA CAC AAG 
GC, U32 – GGG TGT AAC AAG CTG GTG TTC. For 2LTR circles: MH535 – 
AAC TAG GGA ACC CAC TGC TTA AG, MH536 – TCC ACA GAT CAA GGA 
TAT CTT GTC.  For Full product: LTR9 - GCC TCA ATA AAG CTT GCC TTG, 
AA55 - CTG CTA GAG ATT TTC CAC ACT GAC  β-actin- ATC ATG TTT GAG 
ACC TTC AA, 3' β-actin- AGA TGG GCA CAG TGT GGG T. QPCR reactions 
using SYBR green were performed using Eppendorf real plex master cycler ep 
and BioRad SYBR SuperMix according to manufacturer's protocol. Cycling 
conditions used were 95°C for 2 min, followed by 40 cycles of 95°C 30s, 58°C 
30s, and 72°C 30s, and a final extension of 5 minutes at 72°C for all PCR 
products. Cycle threshold value was used to normalize the DNA amounts for the 
Jurkat cells. Fold difference was calculated using the Delta Ct method. The melt 
curve as well as analysis of the PCR products by agarose gel electrophoresis 
confirmed the presence of one product at the expected size (data not shown). 
DNA input was controlled by qPCR amplification of a fragment of the β-actin 
gene. 
 
Viral entry and binding assays and immunoblotting 
For VSVG binding and entry assays 1 x 106 KG-1 and Jurkat cells were 
incubated with HIV-VSVG (MOI = 5) at 4˚C for 1 hour. Infection was started by 
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moving the cells into 37˚C. Cells were collected at different time points, washed 
10 times with cold PBS. For the entry assay cells were treated with 0.05% 
Trypsin-EDTA (Life Technologies) for 15 minutes at 37˚C to remove surface 
bound virions and then washed 10 times again with cold PBS. Washed cells 
were lysed with lysis buffer (20 mM Tris-HCl [pH 8.0], 1 mM CaCl2, 150 mM 
NaCl, 1% Triton) and proteins were separated with SDS-PAGE on 12% 
polyacrylamide gel. Presence of virus and cell proteins were detected with 
immunoblotting using the antibodies indicated. Same procedure was followed for 
RD114 mediated HIV-1 binding and entry assays. Cells were collected at 2 hours 
post infection and either treated with Trypsin-EDTA (for entry) or just washed (for 
binding). 
Flow cytometry based VSVG binding assay was performed by first incubating 1 x 
106 KG-1 and Jurkat cells with HIV-VSVG (MOI=5) at 4˚C for 2 hours. Following 
extensive washes with cold PBS samples were incubated with anti-VSVG 
antibody for 1 hour at 4˚C. Unbound antibody was washed with cold PBS and 
secondary antibody with conjugated Alexa488 was added to the cells and 
incubated at 4˚C for 1 hour. Following several washes with cold PBS fluorescent 
cells were detected using Becton-Dickinson FACScalibur.  
For detection of gp96 expression, 5 x 105 KG-1 and Jurkat cells were lysed with 
lysis buffer (20 mM Tris-HCl [pH 8.0], 1 mM CaCl2, 150 mM NaCl, 1% Triton), 
proteins were separated with 12% SDS-PAGE and gp96 was detected with 
immunoblotting. 
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LDL uptake assay  
1 x 106 KG-1 and Jurkat cells were plated into 6 well plates in serum free media. 
3 µg/mL DiI-LDL was added and the cells were incubated for 4 hours. The cells 
were then washed 3 times with PBS and treated with 0.05% Trypsin-EDTA at 
37˚C for 15 minutes to remove surface bound DiI-LDL. After several washes with 
PBS, fluorescence of cells was scored using Becton-Dickinson FACScalibur. 
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Figure 4-1. Infectivity of different human cell lines with HIV-VSVG. Several 
human cell lines were transduced with different amounts of HIV-VSVG that was 
produced in 293T cells. Percent of GFP positive cells were determined using flow 
cytometry 3 days post infection. 
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Figure 4-2. KG-1 cells cannot be infected with VSVG pseudotyped 
retroviruses. A. KG-1 and Jurkat cells were infected with HIV-VSVG and MLV-
VSVG at an MOI of 10. Percent of GFP positive cells were determined using flow 
cytometry 3 days post infection. B. KG-1 and Jurkat cells were infected with 
Measles virus encoding GFP at an MOI of 3. Percent of GFP positive cells were 
determined using flow cytometry 48 hours post infection. C, D and E. KG-1 and 
Jurkat cells were infected with HIV-VSVG at an MOI of 1. Viral cDNA products 
were quantified using qPCR for integrated provirus at 6 weeks post infection (C), 
for 2LTR circles at 48 hours post infection (D) and for first jump products 8 hours 
post infection (E). 
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Figure 4-3. VSVG binding is impaired in KG-1 cells. A. KG-1 and Jurkat cells 
were infected with VSV-eGFP at an MOI of 50. Percentage of GFP positive cells 
were determined at 24 hours post infection using flow cytometry. B. KG-1 and 
Jurkat cells were infected with HIV-VSVG at an MOI of 5. Cells were collected at 
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indicated times, washed, treated with Trypsin-EDTA and the lysates were used 
for immunoblotting with the indicated antibodies. Ctrl indicates non-infected cells. 
C. KG-1 and Jurkat cells were infected with HIV-VSVG at an MOI of 5. Cells 
were collected at indicated times, washed and the lysates were used for 
immunoblotting with the indicated antibodies. D and E. KG-1 (D) and Jurkat (E) 
cells were incubated HIV-VSVG at an MOI of 5 at 4˚C for 2 hours. Cells were 
collected, washed and incubated with an antibody against VSVG and a 
secondary antibody with Alexa488 conjugated to it. Surface bound virions were 
detected with flow cytometry. Yellow line: Non - infected cells. Blue line: Non - 
infected cells incubated with antibodies. Black line: Infected cells incubated with 
antibodies. 
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Figure 4-4. KG-1 cells express gp96 and can functionally take up LDL. A. 
Immunoblots of KG-1 and Jurkat cell lysates using gp96 and GAPDH antibodies. 
B and C. KG-1 (C) and Jurkat (B) cells were incubated with DiI-LDL for 4 hours 
and fluorescent cells were detected using flow cytometry. 
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Figure 4-5. RD114 mediated entry deficiency in KG-1 cells. A. Jurkat and KG-
1 cells were infected with RD114 pseudotyped HIV-1 (MOI = 5) and MLV (MOI = 
1) encoding GFP. Percentage of GFP positive cells were determined using flow 
cytometry 3 days post infection. B and C. KG-1 and Jurkat cells were infected 
with RD114 pseudotyped HIV-1 at an MOI of 1. Viral cDNA products were 
quantified using qPCR for first jump products 8 hours post infection (B). for 2LTR 
circles at 48 hours post infection (C). D. KG-1 and Jurkat cells were infected with 
RD114 pseudotyped HIV-1 at an MOI of 5. Cells were collected at 2 hours, 
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washed, treated with Trypsin-EDTA or not and the lysates were used for 
immunoblotting with the indicated antibodies. Control indicates non-infected cells.  
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Figure 4-6. KG-1 cells are refractory to infection with retroviruses 
pseudotyped with amphotropic envelope A. KG-1 and Jurkat cells were 
infected with 4070A pseudotyped MLV-GFP at different MOIs using 
spinoculation. Percentage of GFP positive cells were determined 3 days post 
infection. B. KG-1 and Jurkat cells were infected with 4070A pseudotyped HIV-
GFP at different MOIs using spinoculation. Percentage of GFP positive cells 
were determined 3 days post infection. C, D and E. KG-1 and Jurkat cells were 
infected with 4070A pseudotyped HIV-1 at an MOI of 1. Viral cDNA products 
were quantified using qPCR for first jump products 8 hours post infection (C), for 
2LTR circles at 48 hours post infection (D) and for integrated provirus at 6 weeks 
post infection (E). 
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Figure 4-7. KG-1 cells can maintain integrated provirus and HIV-1 
accessory factors don't rescue the block to infection. A. KG-1 and Jurkat 
cells were infected with 4070A pseudotyped HIV-GFP at an MOI of 0.5 using 
spinoculation. Percentage of GFP positive cells were determined 4 weeks post 
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infection. B. KG-1 and Jurkat cells were infected with 4070A pseudotyped MLV-
GFP at an MOI of 1 using spinoculation. Percentage of GFP positive cells were 
determined 4 weeks post infection. C. KG-1 and Jurkat cells were infected with 
4070A pseudotyped HIV-GFP containing all the accessory factors (HIG). 
Percentage of GFP positive cells were determined 3 days post infection. 
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Chapter 5 
 
Conclusions and Future Experiments 
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The goal of this dissertation is to increase our understanding of the interaction 
between HIV-1 and the host cell. I utilized two strategies to achieve this goal: 1. 
Investigating the role of a ubiquitous cellular pathway (the N-end rule) in HIV-1 
replication cycle. 2. Characterizing a human cell line resistant to HIV-1 and HIV-1 
based vectors 
 
N-end rule pathway had previously been implicated in the HIV-1 life cycle both 
directly through RNAi screens and indirectly via the observation that integrase 
can be a substrate for this pathway when expressed ectopically in cells (49, 203, 
205). Using this information I investigated the effect of the N-end rule pathway on 
the integrase protein of HIV-1 and MLV during the early phase of viral life cycle. 
As presented in Chapter 2, the results obtained using cells that are genetically 
impaired in the N-end rule pathway and viruses that have mutations at the 
integrase N-terminal residue indicate that integrase is not a direct target of the N-
end rule pathway during HIV-1 and MLV life cycles. Integrase or any other viral 
proteins that are part of the GagPol polyprotein cannot be a substrate of N-end 
rule during the late phase of the viral life cycle since these substrates are only 
revealed after maturation. Therefore, the N-end rule can only directly act on 
these proteins when they are delivered into the cell via the viral particle. 
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Interestingly depletion of E3 ligases of the N-end rule pathway impacted HIV-1 
and MLV infections differently. Ubiquitous nature of this pathway combined with 
the results we obtained on integrase suggests that this difference is caused by 
the effect of N-end rule impairment on the stability of one or more host proteins. 
Because only a limited number of targets of N-end rule pathway in the 
mammalian cells have been identified, the reason for the observed decrease in 
HIV-1 infectivity may not be trivial to find. However there are other potential 
avenues for further investigating the impact of the N-end rule pathway on HIV-1 
life cycle.  
 
One such experiment would be to knockout UBR1, 2 and 4 in human cells. With 
the development of efficient site specific targeting technologies in recent years, it 
is now possible to mutate a specific gene or even a specific region in a gene with 
relative ease in cell culture (309-311). Experiments presented in chapter 2 relied 
on mouse embryonic fibroblasts with gene knockouts. It is important to test 
whether depleting the UBR proteins of the N-end rule will have the same effect 
on HIV-1 or MLV infectivity in human cells. In addition UBR4 depletion was 
achieved through RNAi, hence reduced infection that we observed could be 
enhanced when this protein is completely absent in the cells. Moreover, UBR5 
was previously identified as an HIV-1 host cell factor in a genomewide RNAi 
screen (49). In this study we didn't test the role of UBR5 in N-end rule and 
integrase due to the fact that integrase stability was previously shown to be 
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impacted in cells depleted of UBR1,2 and 4. Given the observed redundancy 
between UBR proteins, knockout studies may reveal useful information about the 
effect of UBR5 on HIV-1 infection. 
 
As mentioned above, the N-end rule cannot have a direct effect on viral proteins 
with destabilizing N-terminal residues in the late phase of the viral replication. 
However, cellular proteins that are substrates of the N-end rule pathway may be 
involved during the late phase. This can be tested by transfecting human cells 
engineered for UBR knockouts with the three plasmid system described in the 
previous chapters for HIV-1 production. Comparison of production of Gag, 
GagPol as well as the amount of virus released from the cells with differential N-
end rule pathway capabilities will reveal whether the N-end rule pathway affects 
the late phase of retroviral life cycle. 
 
While studying the potential impact of the N-end rule pathway on HIV-1 RNase 
H, we discovered an intriguing phenomenon; changing the N-terminal residue of 
RNase H into a structurally different amino acid than the conserved residue led to 
the absence of RT in the virus particle. Our results, as presented in chapter 3, 
indicate that this is caused by the degradation of RT in the virus particle after its 
release from the GagPol polyprotein following virus budding. Interestingly we 
found a defect in heterodimerization of RT subunits in one of the RNase H 
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mutants. This is the first time a residue in RNase H has been shown to affect RT 
subunit dimerization. At this point it is unknown whether this defect in subunit 
binding is the cause of intravirion RT degradation. There is evidence from 
previous studies of a decrease in the amount of RT in virus particles when 
heterodimerization impaired mutants were used (268, 269). While this decrease 
doesn't match the substantial degradation we observed for all the unstable 
mutants generated in this dissertation, it is possible that the N-terminal RNase H 
residue is more critical for subunit binding than the previously tested residues. 
Therefore further experimentation is needed to better understand the role of this 
residue in RT subunit interactions. A useful starting point would be to test the 
heterodimerization of RT subunits in the other RT unstable RNase H mutants we 
generated. Some of the mutants showed residual levels of RT in the virus 
particle. Similarly a lessened affect may be observed in subunit binding 
impairment. In addition, the rest of the naturally occurring amino acids can be 
tested for both intravirion RT stability and heterodimerization. Interestingly the RT 
inhibitor antiretroviral drug efavirenz has been shown to enhance the 
dimerization of RT subunits and rescue a defect in RT subunit dimerization in 
some RT mutants (266, 312). Testing the effect of efavirenz in the RNase H N-
terminal mutants may reveal clues about the mechanism of the 
heterodimerization defect. 
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Results presented in chapter 3 suggest that one or more cellular proteases may 
be responsible for the degradation of intravirion RT with N-terminal RNase H 
mutations. Unfortunately we were unable to test this stringently in virus particles 
because the RNase H proline mutant had a defect in dimerization of RT subunits 
as mentioned above. Since our results indicate that RT needs to be released 
from the fusion protein to be subjected to degradation in the virus particle, testing 
of RNase H mutant RT degradation in protease inactive virions presents a 
challenge. It is possible that N-terminal mutants that contain other amino acids 
that we haven't tested are still subject to the same degradation while retaining the 
subunit binding ability.  
 
One of the RNase H N-terminal mutants (Methionine) showed residual infectivity 
in Jurkat cells. Using replication competent HIV-1 it may be possible to isolate 
viruses that rescue the partial RT degradation observed in the methionine 
mutant. Sequencing of these mutants may reveal important sites for RT stability 
including possible sites that may rescue the dimerization defect we observed for 
the proline RNase H mutant. If any of these mutations can rescue the RT subunit 
dimerization without changing RT stability inside viral particles, it can be used to 
test whether viral protease is responsible for this degradation or not. 
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Whether the degradation of RT in RNase H mutants is mediated by a cellular 
protease or the viral protease, it represents an interesting drug target in RT. 
Targeting of protease cleavage sites is not a new idea. In fact an experimental 
antiretroviral called bevirimat was shown to inhibit the maturation process of HIV-
1 Gag by binding to the protease cleavage site between capsid and p1 spacer 
protein (313). Even though this drug wasn't specifically designed to bind a 
protease cleavage site, it shows the viability of this type of targeting.  
 
In the final part of this dissertation, I have examined the resistance to retroviral 
infection in a human myeloid cell line. Remarkably KG-1 cells turned out to be 
defective in binding to VSVG. To my knowledge this represents the first human 
cell line that is incapable of supporting entry by VSV. Future experiments can 
elucidate the reason behind this binding defect. My preliminary observation 
suggests that this defect may be dominant, indicating a host protein may be 
preventing the VSVG receptor to be synthesized or to reach the cell surface. This 
preliminary analysis needs to be confirmed and if heterokaryons reveal that the 
block is indeed dominant, cDNA library transfer can be used to identify the gene 
responsible. If the opposite is true, it may be possible to transduce KG-1 cells 
with a cDNA library from a permissive cell type using a retroviral vector with 
amphotropic envelope. Low levels of infectivity I observed with these vectors may 
be sufficient to identify the missing host factor. A similar strategy can be used to 
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find the identity of the host factor responsible for causing the restriction of 
retroviral infection and RD114 entry defect. 
 
Resistance to amphotropic envelope pseudotyped retroviruses observed in KG-1 
cells seems to be caused by a block at late reverse transcription or nuclear 
import. Even though I observed similar resistance to viruses expressing all HIV-1 
accessory factors, it is possible that another retroviral accessory factor, Vpx, may 
relieve this inhibition. This can be tested by infecting KG-1 cells with HIV-2 or by 
transducing the cells with virus like particles containing Vpx before infecting them 
with HIV-1 or MLV (183-185, 314, 315). A recently identified target of antagonism 
by Vpx, SAMHD1, is unlikely to be acting on these cells since as dividing cells 
KG-1 cells require high levels of dNTPs. Nevertheless it is possible that an 
unidentified host factor that is counteracted by Vpx may be responsible for the 
resistance to retroviral infection in these cells. 
 
In conclusion, the studies presented in this dissertation have increased our 
understanding of the interaction of HIV-1 with host cell factors. It was previously 
hypothesized that HIV-1 integrase may be a target for the N-end rule pathway. I 
have accumulated substantial evidence to contradict this claim using N-end rule 
deficient cells and Integrase N-terminal mutants of HIV-1 and MLV. Moreover in 
an effort to understand the role of RNase H N-terminal residue in HIV-1 infectivity 
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I have discovered that this residue is not only critical for viral infectivity, it is also 
important for RT stability in the virus particle and dimerization of RT subunits. In 
addition to the studies of N-end rule and N-terminal residues of retroviral 
proteins, I have also identified the first human cell line that is resistant to binding 
by VSVG. This observation may be used to identify critical components of VSVG 
mediated entry into cells. Moreover my results indicate that this cell line, KG-1, is 
refractory to retroviral infection due to a block in late reverse transcription or 
nuclear import. Further studies of KG-1 cells may reveal the identity of a novel 
restriction factor or a critical cofactor in HIV-1 infection. 
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